The European
Multidisciplinary Cancer Congress Integrating basic & translational science, surgery, radiotherapy, medical oncology & care stockholm, 23-27 SEPTEMBER 2011 ADVANCE PROGRAMME & CALL FOR ABSTRACTS
www.ecco-org.eu
In partnership:
The Organising Committee would like to gratefully acknowledge the vital support, willing and collaboration of all Member Societies of ECCO – the European CanCer Organisation, without which this Congress would not be possible.
Acknowledgement
FOUNDING MEMBER
European Association for Cancer Research
European Oncology Nursing Society (EONS)
European Association of Neuro-Oncology (EANO)
European Association of Urology (EAU)
European Society of Oncology Pharmacy (ESOP)
European Society of Breast Cancer Specialists (EUSOMA)
European Society for Medical Oncology (ESMO)
European Society of Surgical Oncology (ESSO)
European Organisation for Research and Treatment of Cancer (EORTC)
European Society for Therapeutic Radiology and Oncology (ESTRO)
European Society of Gynaecological Oncology (ESGO)
European Society for Paediatric Oncology (SIOPE)
European School of Oncology (ESO)
Full members
Breast International Group (BIG)
European Association of Nuclear Medicine (EANM)
European Group for Blood and Marrow Transplantation (EBMT)
European Society of Skin Cancer Prevention (EUROSKIN)
Flims Alumni Club (FAC)
Myeloma Euronet
Association of European Cancer Leagues (ECL)
European Breast Cancer Coalition (Europa Donna)
Advisory members Organisation of European Cancer Institutes (OECI)
International Union Against Cancer (UICC)
Official Media Partners On behalf of the Executive Scientific Committee, we would like to acknowledge the collaboration and support of our official media partners:
OncologySTAT® One Source, Many Resources.
European Prostate Cancer Coalition (Europa Uomo)
Table of Contents Chairs’ Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Save the Dates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Congress Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Scientific Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Programme at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Programme Frames . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Detailed Advance Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Call for Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Abstract Policies & Regulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Abstract Preparation & Submission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Abstract Selection Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Late Breaking Abstracts – Policy & Regulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Embargo Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Abstract Topic Categories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Fellowship Grants & Educational Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 Registration Form . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 Scientific Programme Tracks: Chairs & Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Top 10 Reasons to Attend . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 Accommodation & Local Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 Accommodation Form . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Chairs’ Welcome The first jointly organised multidisciplinary Cancer Congress – ECCO 15 – ESMO 34, Berlin, September 21 -24 2009, marked an important milestone in advancing cancer research and treatment across Europe by drawing a record multi-stakeholder audience of almost 15.000 participants, and presenting more cutting-edge and late breaking data than ever before. Thanks to the vision, expertise and dedication of over 150 leading experts, who have tirelessly worked together to devise a comprehensive Scientific Programme of excellence synonymous with our Congresses, we can and will do even better. The 2011 European Multidisciplinary Cancer Congress: the multidisciplinary mass gathering and celebration of European basic, translational and clinical studies Building on the great successes of our Congresses past, as of this year we are bringing together the 16th ECCO, 36th ESMO, 30th ESTRO Congresses to form the European Multidisciplinary Cancer Congresses, organised in partnership with the essential contribution of all ECCO’s other Founding Members - ESSO, EACR, EONS and SIOPE. Further, as the Congress tagline ‘Integrating basic & translational science, surgery, radiotherapy, medical oncology & care’ suggests, the uniqueness of our Congresses lies in the multidisciplinary and multi-professional scope, appeal and draw. The European Multidisciplinary Cancer Congresses are consequently the only multidisciplinary and multiprofessional educational opportunity in oncology to take place in Europe – a fact that underpins the relevance, role and participation of each and every specialty in oncology. Collectively advancing European cancer therapeutics and prevention: the 2011 European Multidisciplinary Cancer Congress Call for Abstracts While the Scientific Programme will unquestionably deliver breakthrough advances and insight in scientific and clinical research, patient management and practice through an outstanding range of scientific and educational symposia, special sessions, teaching lectures, workshops, legendary ‘heated’ oxford style debates and more, the best discussions will also be triggered by your abstracts. Only with your results will we be able to ultimately impact directly on our patients through more effective prevention strategies, earlier diagnosis and better treatment modalities, as well as succeed in bringing cutting edge data back to Europe. In the hope that you will select our meeting - the largest European platform at which to present the latest, groundbreaking data, as your definitive choice, we invite you to submit your practice changing data which will be mature in 2011. Just some of the results we want to see in Stockholm include those from practice-changing prospective Phase III clinical trials, Phase II studies showing anti-tumour activity in a novel context, early clinical trials with novel proof-of-principle data, and demonstrations of novel cancer biology with therapeutic implications. 2
Back To table of contents
The Scientific Programme: a 33 Track educational opportunity In 2009 we promised a Scientific Programme of ‘firsts’ – our 2011 Congress will continue the trend. To further guarantee the multidisciplinary and multi-professional appeal unique to our Congresses we have incorporated 5 brand new Tracks including Industry as well as Oncotechnology. Introduced to enhance the multidisciplinarity and multiprofessional appeal of the Congress, these Tracks will present new technologies including new diaganostic equipment, advanced radiotherapy technologies, teleoncology development and novel options for laboratory research that are of key to improving strategies in both patient care and in cancer research. As the premier European cancer meetings, it is a logical consequence that each Congress builds on successes of the past by broadening in spectrum and scope, thereby setting new standards within the international cancer conference arena. Launched at our 2009 Congress, the Oncopolicy Track will continue to embrace all stakeholders to address and tackle issues of prime importance to the European cancer community head-on, as well as promote and foster continued improvement at EU Level. Similarly, both the Patient Advocacy/Ethics Track and the Oncology Nursing Track will continue to be fully integrated within the core Scientific Programme to ensure that we can all participate in discussion on issues of shared concern to cancer patients, advocates and professionals as well as allow for the participation of cancer nurses in all Programme sessions which will be imperative in identifying future directions aimed at improved patient care across Europe. Totalling at 33 Tracks, the Scientific Programme has been structured to serve multidisciplinarity through the essential interconnectivity between all disciplines, professions and individual tumour types. No stone has been left unturned – this meeting is a must-attend for all! In the trust that you will agree with us, we look forward to receiving your registration, reviewing your exciting data, and to collectively advancing European cancer therapeutics and prevention at the 2011 European Multidisciplinary Cancer Congress, 23 – 27 September 2011, Stockholm.
Michael Baumann, ECCO President and Congress Chair David Kerr, ESMO President Jean Bourhis, ESTRO President Anne-Lise Børresen-Dale, Scientific Co-Chair (ECCO) Jean Charles Soria, Scientific Co-Chair (ESMO) Roger Henriksson, National Organising Committee Chair
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Save the Dates Early Rate Registration Closes (receipt of payment) Regular Rate Registration Closes (receipt of payment)
SAVE THE DATES
Registration 4 April 2011 8 August 2011
Abstract Submission Regular Abstract Submission Opens Regular Abstract Submission Closes Late Breaking Abstract Submission Opens Late Breaking Abstract Submission Closes Fellowship Grant Application Closes Housing Reservation Closes
31 January 2011 18 April 2011 27 July 2011 10 August 2011 18 April 2011 1 August 2011
Congress Secretariat & Venue Congress Secretariat Congress Venue c/o ECCO – the European CanCer Organisation Stockholmsmässan Avenue E. Mounier 83 (Stockholm International Fairs) B-1200 Brussels Mässvägen 1 (visitor’s address) Tel: +32 (0)2 775 02 01 Älvsjö Fax: +32 (0)2 775 02 00 SE-125 80 Stockholm, Sweden Email: stockholm2011@ecco-org.eu Tel: +46 (0)8 749 41 00 www.ecco-org.eu
www.stofair.se
Exhibition & Sponsorship The 2011 European Multidisciplinary Cancer Congress Exhibition represents an essential and integral element of the Congress, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the oncology field. For information about sponsorship and exhibition opportunities please contact: Bruno De Man, Email: bruno.deman@ecco-org.eu, Tel: +32 (0)2 775 02 04. To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECCO website at: www.ecco-org.eu.
Accreditation for Continuous Medical Education (CME) Application for accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
Back To table of contents
3
Congress Committees Organising Committee Michael Baumann (DE) ECCO President & Congress Chair David Kerr (UK) ESMO President & ECCO Board Member Jean Bourhis (FR) ESTRO President Cornelius J. van de Velde (NL) ECCO President Elect Anne-Lise Børresen-Dale (NO) Co-Scientific Chair & ECCO Treasurer (ECCO) Jean Charles Soria (FR) Co- Scientific Chair (ESMO) Roger Henriksson (SE) National Organising Committee Chair
Executive Scientific Programme Committee Anne-Lise Børresen-Dale (NO) Co-Scientific Chair (ECCO) Jean Charles Soria (FR) Co-Scientific Chair (ESMO) Jean Bourhis (FR) Radiotherapy Vice Chair Peter Naredi (SE) Surgery Vice Chair Dirk Schrijvers (BE) Co-Education Chair Rolf Stahel (CH) Co-Education Chair Roger Henriksson (SE) National Organising Committee Chair Michael Baumann (DE) ECCO President & Congress Chair David Kerr (UK) ESMO President & ECCO Board Member
National Organising Committee Roger Henriksson Chair Håkan Mellstedt Vice Chair
National Organising Committee Members Jonas Bergh Elisabeth Åvall Lundqvist Michael Bergqvist Beatrice Melin Åke Borg Peter Naredi Jan-Erik Damber Sten Nilsson Gunilla Enblad Monica Nister Bengt Glimelius Arne Östman Per Hall Göran Roos Johan Hansson Lena Sharp Håkan Hedman Anders Widmark Matthias Löhr Björn Zackrisson Please see page 45 for Track Chairs & Experts
4
Back To table of contents
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Scientific Programme: Programme at a Glance Thursday 22 September 2011
07:00 – 19:00
Friday 23 September 2011
08:00 – 21:00
Saturday 24 September 2011
07:00 – 18:00
Sunday 25 September 2011
07:00 – 18:00
Monday 26 September 2011
07:00 – 18:00
Tuesday 27 September 2011
07:00 – 12:00
PROGRAMME AT A GLANCE
Registration Opening Hours
Opening Event Friday 23 September
19:30 – 21:30
The 2011 Stockholm Cancer Congress Opening Event will take place on Friday 23 September from 19:30 onwards in Hall A1 of the Congress Centre. In celebration of the largest and premier cancer meeting in Europe, we invite you to what promises to be an unforgettable evening in the company of friends and guests as well as enjoy a trio of live entertainment followed by a welcome reception serving local fare, delicacies and drinks.
Scientific Programme Sessions (*) Saturday 24 September 2011
08:00 – 18:00
Sunday 25 September 2011
08:00 – 18:15
Monday 26 September 2011
08:00 – 18:00
Tuesday 27 September 2011
08:00 – 12:30
(*) All timings are subject to change. For updates on the programme please visit and bookmark ECCO’s website at: www.ecco-org.eu (select ‘Congresses and conferences’, ‘2011 Stockholm Cancer Congress’)
Corporate Satellite Symposia The 2011 Stockholm Cancer Congress Corporate Satellite Symposia are additional educational opportunities officially reviewed and approved by the Congress Scientific Committee. Offering multidisciplinary programmes to naturally complement the general concept of the official Scientific Programme, these sessions are the perfect forum for participants to discover the very latest scientific data and developments from with our industry. To browse the Corporate Satellite Symposia agenda and add to your 2011 Stockholm Cancer Congress diary please see page 47.
Back To table of contents
5
6
20:00
18:30
18:00
16:00
15:45
15:15
14:15
13:45
11:15 11:15
11:00 11:00
Proffered paper session
Proffered paper session
ES
Colorectal
The Jungle of Treatments in Advanced Colorectal Cancer
ES
Breast
Metastatic Breast Cancer: What Do the Different Treatment Modalities Add to Survival?
Best and Late Breaking Abstracts
Presidential I
P.P.
Colorectal
T.L.
New Insights in the Management of Renal Cancer
GU-other
Anti-Angiogenic Strategies for Cancer
Translational
S.S.
Immune System and Tumour Response to Radiotherapy
Radiotherapy
Spec.S.
Probiotics, Calories and Cancer Care
Nursing
S.S.
Developments in Surgical Oncology
Nursing
Spec.S.
Telethinking in Cancer Care
Improving the Therapeutic Ratio of Radiotherapy: New Concepts to Protect Normal Tissues
S.S.
Nursing
Radiotherapy
S.S.
Welcome and Award Session
Nursing
Opening
Radiotherapy of Prostate Cancer
What Are the Expected Developments in Medical Treatment of Bladder Cancer
T.L.
Radiotherapy
T.L.
GU-other
T.L.
Head and Neck: What Next in Biologically Targeted Therapy?
Head & Neck
S.S.
Late Toxicity Treatment of Head and Neck Cancer
Head & Neck
Spec.S.
Proffered paper session
Head & Neck
P.P.
The Current Treatment of Nasopharyngeal Cancer
Head & Neck
S.S.
Satellite Symposia
Clinical Trial Methodology
Regulatory
S.S.
Issues in Economic Evaluation of New Cancer Therapies
Regulatory
Spec.S.
Small RNAs and Cancer
Basic science
P.P.
Melanoma Realising the Potential in Immunotherapy
Melanoma
S.S.
Too Little or Too Much Surgery for Melanoma
Melanoma
Spec.S.
Proffered paper session
Melanoma
AES
The Challenges of Rare Cancers
Patients
AES
Patient Information on Trial
Patients
CRT
Getting Personal - Treatment in the Age of Targeted Therapies
Patients
P.P.
Proffered paper session
Nursing
P.P.
Adolescent and Young Adult Cancer Patients: Are We Meeting Their Needs?
Nursing
Spec.S.
Proffered paper session
Nursing
T.L.
Molecular Cancer Epidemiology - the Next Generation
Epidemiology
S.S.
Preventing Cervical Cancer
Epidemiology
Spec.S.
Molecular Imaging of Hypoxia
Imaging
S.S.
To PET or Not to PET: What Are the Indications?
Imaging
T.L.
Role of the Microenvironment in Lymphomas
Haem.
S.S.
PET-Based Treatment Decisions in Hodgkin Lymphoma
Haem.
Spec.S.
Proffered paper session
Haem.
P.P.
Advances in the Treatment of Myeloma
Haem.
AES= Advocacy/Ethics - CRT = Court Room Trial - DEB= debate - T.L.= Teaching Lecture - E.S.= Educational Symposium - PP=Proffered Papers - S.S.= Scientific Symposium - SpecS= Special Session
Optimal Treatment for a 72-Year-Old Patient With Stage III-N2 NonSmall Cell Lung Cancer
Lung
S.S.
The Management of Penile Cancer
Peritoneal Surface Oncology Evidence for Locoregional Treatment
S.S.
Spec.S.
GU-other
Spec.S.
Proffered paper session
GU-other
P.P.
Management of Early Non-Small Cell Lung Cancer
Lung
Surgical
Proffered paper session
Lung
P.P.
Management of Local Recurrence of Rectal Cancer
Breast Cancer in the Elderly: Different Treatment Modalities
P.P.
T.L.
Colorectal
T.L.
Breast
Breast
Welcome, Keynote Lectures
09:00 Opening Session
08:45
08:00
Saturday 24 September 2011
T.L.
Research Strategy of the Paediatric and Adolescents European Tumour Groups
Paediatric
S.S.
Immunotherapy-the Future
Translational
Spec.S.
Long Term Follow Up in Childhood and Adolescent Cancer
Paediatric
S.S.
Protein Homeostasis
Basic science
S.S.
New Image Guided Cancer Therapies
OncoTech
S.S.
Monitoring Tumour Response to Therapy - What Do the Images Tell Us?
Imaging
Spec.S.
Nanotechnologies for Targeted Drug Delivery
OncoTech
20:15
18:45
18:15
17:15
16:45
16:00
15:00
14:45
14:15 14:30
13:15
12:15 12:30
11:00 11:30
09:00
08:45
08:00
7
Tailored Chemotherapy in Colon Cancer
Optimal Treatment for Advanced Ovarian Cancer
European Society for Medical Oncology (ESMO) Awards Session
Soc.S.
Colorectal
Gynaecological
ES
Best and Late Breaking Abstracts
Presidential II
Do We still need to Understand the Cancer Genome?
S.S.
Proffered paper session
Proffered paper session
Keynote
P.P.
Colorectal
P.P.
P.P.
Spec.S.
Proffered paper session
GU-Prostate
European Society for Therapeutic Radiology and Oncology (ESTRO)
Soc.S.
ECCO/ASCO Scientific Symposium
General
S.S.
Current Issues in the Management of Germ Cell Tumours
T.L.
DEB
European Society of Surgical Oncology (ESSO) - Tailored Treatment for Older Cancer Patients - A Multidisciplinary approach
Soc.S.
This House Believes That Surgery is the Mainstay for the Treatment of PT2 Bladder Cancer
GU-other
T.L.
T.L.
T.L.
European Society of Gynaecological Oncology (ESGO)
Soc.S.
Screening for Cancer: Sense and Sensibilities
Epidemiology
ES
Esophageal Cancer - Ways to Improve Outcome
Surgical
Spec.S.
Tumour Microenvironment
Basic science
S.S.
New Technology in Radiotherapy
European Association for Cancer Research (EACR)
Soc.S.
Improved Pain Control Through a Collaborative Approach Between Oncology, Pain and Palliative Care Specialists
Symptom science
S.S.
Stem Cells
Basic science
Spec.S.
Not Just Research Subjects, but Research Allies – Patient Involvement in the Design, Conduct and Dissemination of Clinical Trials
Patients
Spec.S.
Cancer Research - Ethics and Challenges
Patients
AES
Cancer and the Internet
Patients
AES
Cancer at Any Age - Ethics and Challenges
Melanoma Therapy Realising the Potential in Targeted Therapy
AES
Thyroid – Emerging Tumour
Patients
S.S.
Uterine Sarcomas: a Multidisciplinary Challenge
T.L.
Head & Neck
Melanoma
Satellite Symposia
European Society of Breast Cancer Specialists (EUSOMA)
Soc.S
This House Believes That Prospective Randomised Trials Should Be Stopped If At Interim Analysis a Sufficient Positive Effect Can Be Detected
Regulatory
DEB
Cross-Over in Trials
Regulatory
Spec.S.
The Application of Pharmacometrics in Oncology
Regulatory
S.S.
Growth Factor Receptor Related Therapy for Gastric Cancer
Radiotherapy Noncolorectal Gynaecological
T.L.
Flims Alumni Club (FAC)
Soc.S
The Role of Medical Technology in Building a Sustainable Cancer Care
INDUSTRY
S.S.
Endpoints in Clinical Trials
CNS
Spec.S.
Proffered paper session
CNS
P.P.
Adjuvant Chemotherapy and Radiation Therapy in High Risk Penile Cancer
GU-other
T.L.
European Association of Nuclear Medicine (EANM)
Soc.S
This House Believes That EpithelialMesenchymal Transition is Essential for Tumour Progression
Basic science
DEB
Calories and Cancer
Epidemiology
Spec.S.
Proffered paper session
Nursing
P.P.
DNA Repair as Treatment Target
Basic science
T.L.
T.L.
European Society of Oncology Pharmacy (ESOP)
Soc.S
Brain Tumours in Children and Adolescents
Paediatric
S.S.
Multidisciplinary Quality Assurance
Molecular Genetics in LymphomaCurrent Knowledge and New Insights From Highthroughput Technologies
T.L.
Paediatric
Spec.S.
Medulloblastoma
Paediatric
The European Society for Paediatric Oncology (SIOP Europe)
Soc.S
The European Network for Cancer Research in Children and Adolescents (ENCCA) FP7 Project
Programme AT A GLANCE
European Association of NeuroOncology (EANO)
Soc.S
What Knowledge and Attitudes Do Paid Carers of People With Learning Disabilities Have About Cancer?
Nursing
Interactive Workshop
Tips and Tricks to be the Best
Young Oncol.
Spec.S.
General
S.S.
Current Approaches to Adjuvant Therapy of Melanoma
Melanoma
Haem.
S.S.
Diagnostic and Therapeutic Approach of Primary Cutaneous Lymphomas
Haem.
AES= Advocacy/Ethics - DEB= debate - E.S.= Educational Symposium - PP=Proffered Papers - S.S.= Scientific Symposium - Soc.S= Society Session - SpecS= Special Session - T.L.= Teaching Lecture
European Association of Urology (EAU)
Soc.S.
This House Believes That Adaptive Radiotherapy Reduces Side Effects and Allows Treatment Intensification
Novel Targeted Therapies for Metastatic Non-Small Cell Lung Cancer
Soc.S.
DEB
Radiotherapy
Fertility Concerns
This House Believes That Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours
Spec.S.
Nursing
Head & Neck
DEB
Symptom Management
Impact of Tumour Hypoxia on Heterogeneity in Radiation Response
S.S.
Introduction to Lung Cancer Curriculum (Part 1): Basic Science of Lung Cancer
Nursing
Lung
European Oncology Nursing Society (EONS) Couples - (the Prostate Cancer Charity)
T.L.
Nursing
Radiotherapy
S.S.
New Adjuvant Treatments for Locally Advanced Prostate Cancer
GU-Prostate
Spec.S.
New Insights in Molecular Targeting in Radiotherapy
GU-other Radiotherapy
Spec.S.
Proffered paper session
Lung
P.P.
Thymoma
Current Standards and New Trends in the Primary Treatment of Colorectal Cancer
How to Personalise Treatment in Early Breast Cancer
Breast
Highlights Session
T.L.
Lung
T.L.
Colorectal
T.L.
Breast
Sunday 25 September 2011
S.S.
European School of Oncology (ESO)
Soc.S
Assessment Novel Oncotechnology
OncoTech
Spec.S.
Novel Oncoproteomic Technology
OncoTech
20:15
18:45
18:00
17:00
16:45
14:30 14:45
14:15
13:15
12:15 12:30
11:30
11:00
09:00
08:45
08:00
8
Colorectal
Tailored Neoadjuvant Therapy in Rectal Cancer
Breast
How to Understand and to Reverse Drug Resistance in Metastatic Breast Cancer
GU-Prostate
Medical Treatment of Metastatic Prostate Cancer
Breast
Breast Conservation in Young Women With Early Breast Cancer
Advanced Technology for Radiotherapy
How Should We Treat Good Risk Prostate Cancer Focally or Entirely?
Lung
This House Believes That Maintenance Therapy is Standard of Care in NonSmall Cell Lung Cancer
Colorectal
This House Believes That TEM/no Surgery is Reliable in Responders Rectal Cancer Patients After Preoperative Chemoradiation
Breast
This House Believes That Small Biologydriven Trials Will Substitute Large Randomized Clinical Trials in Breast Cancer
Haem. This House Believes That EPO Should Be Part of Daily Cancer Management
This House Believes That the Combination of Multi-Modality Treatment is the Best Approach for the Treatment of High-Risk Prostate Cancer
DEB
Proffered paper session
Noncolorectal
GU-Prostate
DEB
Proffered paper session
Radiotherapy
P.P.
Management of Hilar and Intrahepatic Cholangiocarcinoma
Noncolorectal
Spec.S.
From New Targets to New Drugs in Prostate Cancer
GU-Prostate
This House Believes That Alternative Therapies Have a Place in Cancer Care
Nursing
DEB
Nursing Science
Nursing
S.S.
Developments and Management of Lymphoedema
Nursing
Spec.S.
Survivorship and Life Style Changes After Cancer (Diagnosis)
Nursing
S.S.
Introduction to Lung Cancer Curriculum (Part 2): Epidemiology of Lung Cancer
S.S.
Nursing
Radiation Therapy and Radioisotopes for Bone Metastases: What is Their Real Benefit?
T.L.
Radiotherapy
T.L.
T.L.
T.L.
S.S.
Current Standards and New Trends in Esophageal Cancer
Spec.S.
Tailoring Personalised Medicine for The Future
Codevelopment of investigational agents: industry experience and perspective
Industry
Spec.S.
European Partnership for Action Against Cancer
Oncopolicy Forum
Inequalities in Research
This House Believes That Radiotherapy in Brain Metastases Does Matter
CNS
DEB
High Throughput Technology Platforms for Biomarker Discovery – State of the Art
Challenges and Opportunities in the Development of Personalised Medicine: Perspectives from the Therapeutics and Diagnostics Industries
S.S.
Circulating Tumour Cells
Basic science
Spec.S.
Optimising Treatment in Gliomas
CNS
S.S.
Anaplastic Gliomas: An Emerging Entity
Diagnostic
Oncopolicy Forum
Optimising Access to Cancer Drugs in Europe
Oncopolicy Forum
Inequalities in Clinical Trials
Oncopolicy Forum
Active Surveillance and Prostatectomy
CNS
T.L.
Industry
Spec.S.
Hitting the Right Pathway: New Drugs for New Targets
Satellite Symposia
This House Believes That Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer
Diagnostic
DEB
ESMO-JSMO Joint Symposium - What Can We Learn From Global Clinical Trials?
General
S.S.
Controversies in the Management of Cervical Cancer
Gynaecological Translational
Spec.S.
Proffered paper session
Gynaecological Translational
P.P.
Cancer and Pregnancy: What Should We Know About the Management With Systemic Treatment of Pregnant Women With Cancer?
Gynaecological Noncolorectal GU-Prostate
T.L.
This House Believes That Preoperative Chemotherapy is Not Yet Standard of Care in Softtissue Sarcoma
Sarcoma
DEB
New Avenues in Soft Tissue Sarcoma
Sarcoma
S.S.
Management of Retroperitoneal Sarcoma
Sarcoma
Spec.S.
Proffered paper session
Drug Devel.
P.P.
Status of Therapeutic Anticancer Vaccines
Drug Devel.
T.L.
T.L.
This House Believes That Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
Drug Devel.
DEB
Proffered paper session
BS/TR
Symptom Science Treatment of Dyspnea - What Does the Evidence Support?
P.P.
Health Status in Screening in Elderly Patients - is This the Way Forward?
Elderly
Spec.S.
Proffered paper session
Elderly
P.P.
Geriatrics and Haematological Malignancies
Elderly
T.L.
S.S.
Optimal Care in Rare Cancers
Nursing
Spec.S.
Proffered paper session
Nursing
P.P.
Emergency and Palliative Care
Symptom science
AES= Advocacy/Ethics - DEB= debate - E.S.= Educational Symposium - PP=Proffered Papers - S.S.= Scientific Symposium - Soc.S= Society Session - SpecS= Special Session - T.L.= Teaching Lecture
DEB
Contributors to Better Survival in Colorectal Cancer
Surgical
P.P.
Radiotherapy
GU-Prostate
S.S.
Spec.S.
ESMO Clinical Practice Guidelines
General
S.S.
Stage IIIa Nonsmall Cell Lung Cancer - Views by the Surgeon, Radiotherapist and Medical Oncologist
Lung
Interactive Session With Patient Cases
Spec.S.
Non-Small Cell Lung Cancer - Advanced Disease
Lung
S.S.
Skin-Sparing Mastectomy
DEB
DEB
ES
S.S.
Best and Late Breaking Abstracts
Presidential III
From Cancer Registries to Clinical Practice
Keynote
S.S.
Male Breast Cancer – Neglected Tumour Disease
Surgical
Breast
S.S.
Highlights Session
T.L.
T.L.
Monday 26 September 2011
Diabetes, Obesity and Cancer
General
S.S.
How to Write and Review a Good Article?
Young Oncol.
Spec.S.
Drug Development in Paediatric Oncology
Paediatric
S.S.
This House Believes That Proton Therapy in Paediatric Oncology Improves Clinical Outcome
Paediatric
DEB
The Role of IGFs/ IGF-1R Pathway in Paediatric Malignancies
Paediatric
S.S.
Ewing Sarcoma Treatment
Paediatric
T.L.
S.S.
Dealing With Emotionally Challenging Patients or Families
Nursing
Interactive Workshop
Proffered paper session
OncoTech
P.P.
Novel Radiation Technologies and Strategies
OncoTech
9
17:00
12:30 12:30
11:30
11:00
09:45
09:00
08:45
08:00
Combining Molecular Targeted Agents and Radiotherapy
Triple Negative Breast Cancer – How to Best Treat It and Prevent Relapse?
Colorectal
Strategies of Prolonged Multimodality Treatment in Advanced Patients
Breast
Is the Biology of Metastatic Breast Cancer Similar to the Primary Breast Cancer?
Stereotactic Radiotherapy for Liver Metastases
Treatment of T1N0M0 Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Lobectomy End of Life Care in Oncology
Nursing
Spec.S.
Transitions in Care for Cancer Patients
Nursing
S.S.
Translational Genomics in Breast Cancer
Translational
T.L.
Deb
From Bench to Bedside in Ovarian Cancer
This House Believes That Chemotherapy Has No Further Role in the Treatment of Well Differentiated Neuroendocrine Tumours (NET) This House Believes That Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer
Noncolorectal Gynaecological
DEB
Hepatocellular Carcinoma: Novel Advancements in Diagnosis and Treatment
Noncolorectal Gynaecological
S.S.
Adjuvant Treatment of Pancreatic Cancer
Introduction to Lung Cancer Curriculum (Part 3): Chemotherapy in Lung Cancer
S.S.
Noncolorectal
T.L.
Nursing
T.L. T.L. Sarcoma
Surgical Treatment in Breast Cancer Patients With Distant Metastases
Surgical
Spec.S.
Dealing With Children of Cancer Patients
National Cancer Plans
Oncopolicy Forum
Inequalities in Access to Drugs and Quality of Care
S.S.
Spec.S.
Desmoid Fibromatosis Tumours Representing An Unmet Medical Need
Sarcoma
S.S.
Spec.S.
New insights in Metastatic Processes
S.S.
S.S.
Young Oncol.
This House Believes That Overall Survival is the Only Endpoint for Drug Approval
Young Oncol.
DEB
Head and Neck Cancer Managing the in the Elderly Side Effects Patient
Elderly
Programme AT A GLANCE
Innovations in Early Clinical Trials
Basic science Drug Devel.
Spec.S.
Unravelling Ras PI3 Kinases Targets
Translational Drug Devel.
PARP Inhibiting Strategies: From Proffered paper Molecular session Mechanisms to Rational Clinical Application
PP Sarcoma
ES
Oncopolicy Forum
A Patient With a Soft Tissue T2N0M0 Prostate Cancer, Gleason Sarcomas: Are All Soft Tissue Score 7, PSa 19 Sarcomas Âľg/L - Views By Treated With the Urologist, the Same Radiotherapist Drugs? and Medical Oncologist
GU-Prostate
Interactive Session With Patient Cases
Education
Overview on the Role of Laparoscopic Surgery in Cancer Management
Surgical
T.L.
DEB= debate - E.S.= Educational Symposium - PP=Proffered Papers - S.S.= Scientific Symposium - SpecS= Special Session - T.L.= Teaching Lecture
Radiotherapy
Lung
Spec.S.
Relieving Symptoms of Hormonal Therapies in Patients With Breast Cancer
Spec.S
Partial Breast Irradiation
2010 Consensus On Lung Cancer: New Clinical Recommendations & Current Status of Biomarker Assessment
Spec.S.
Radiotherapy
ES
Lung
S.S.
S.S.
Radiotherapy
Breast
Symptom science
Spec.S.
Best and Late Breaking Abstracts
Presidential IV
Highlights Session
T.L.
T.L.
Tuesday 27 September 2011
Flims Alumni Club Workshop
Detailed Advance Programme Basic Science
Special Session: Stem Cells ■■ 13:15 - 14:15 Chair: R. Toftgård (Sweden) Stem Cells and Skin Cancer Speaker: R. Toftgård (Sweden)
Saturday 24 September 2011
Haematopoietic Stem Cells Speaker: P.G. Pelicci (Italy)
Teaching Lecture: Protein Homeostasis
Stem Cell Self-Renewal Speaker: R. Bjerkvig (Norway)
■■ 08:00 - 08:45 Speaker: T. Jung (Germany)
Scientific Symposium: Small RNAs and Cancer ■■ 11:15 - 13:15 Chair: P.A. Sharp (USA) Chair: R.J. White (United Kingdom) Introduction Speaker: P.A. Sharp (USA) Tumourgenicity of MicroRNAs Speaker: R. Agami (The Netherlands) RNAi - Mechanism, Biology and Application to Cancer Speaker: C.M. Croce (USA) tRNA Control by Tumour Suppressors and Oncogenes Speaker: R.J. White (United Kingdom)
Saturday 24 September 2011 Teaching Lecture: Breast Cancer in the Elderly: Different Treatment Modalities ■■ 08:00 - 08:45 Speaker: R. Audisio (United Kingdom)
Discussion and Roundup
Debate: This House Believes that EMT Is Essential for Tumour Progression ■■ 15:00 - 16:00 Moderator: C. Dive (United Kingdom) EMT Is Essential for Tumour Progression Speaker in Favour: M. Park (Canada) EMT Is NOT Essential for Tumour Progression Speaker Against: I.R. Hart (United Kingdom) EMT Is Essential for Tumour Progression Seconder in Favour: J. Thiery (Singapore) EMT Is NOT Essential for Tumour Progression Seconder Against: L. Norton (USA)
Educational Symposium: Metastatic Breast Cancer: What Do the Different Treatment Modalities Add to Survival? ■■ 16:00 - 18:00 Chair: S.R.D. Johnston (United Kingdom) The Role of Surgery in Metastatic Breast Cancer Speaker: J. Ruiterkamp (The Netherlands) Radiotherapy in Patients With Metastatic Breast Cancer Speaker: W. Budach (Germany) Role of Hormonal Manipulations in Patients With Hormone-Sensitive Metastatic Breast Cancer Speaker: M. Castiglione-Gertsch (Switzerland)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
The Role of Chemotherapy and Targeted Agents in Patients With Metastatic Breast Cancer Speaker: S.R.D. Johnston (United Kingdom)
Concluding Remarks Speaker: R.J. White (United Kingdom)
Monday 26 September 2011
Sunday 25 September 2011
Sunday 25 September 2011
Special Session: Circulating Tumour Cells
Teaching Lecture: How to Personalise Treatment in Early Breast Cancer
■■ 13:15 - 14:15
■■ 08:00 - 08:45
Chair: S. Sleijfer (The Netherlands)
Speaker: T. Sørlie (Norway)
Technological Approaches for CTC Detection Speaker: C. Dive (United Kingdom)
Monday 26 September 2011
Small RNA Regulators of Gene Expression Speaker: P.A. Sharp (USA)
Teaching Lecture: DNA Repair as Treatment Target ■■ 08:00 - 08:45 Speaker: T. Helleday (United Kingdom)
Scientific Symposium: Tumour Microenvironment ■■ 09:00 - 11:00 Chair: M.J. Bissell (USA) Chair: J.W. Pollard (USA) Introduction Speaker: J.W. Pollard (USA) Microenvironment in Breast Cancer Speaker: M.J. Bissell (USA) Stromal Cell Involvement in Cancer Speaker: J.W. Pollard (USA) Anticancer Approaches Based on Tumour Hypoxia and Metabolism Speaker: J. Pouyssegur (France) Tumour - Stroma Interactions in Breast Cancer Metastasis Speaker: C. Isacke (United Kingdom) Concluding Remarks Speaker: M.J. Bissell (USA)
CTC and Micrometastases Speaker: K. Pantel (Germany) Markers for Circulating Tumour Cells Speaker: S. Sleijfer (The Netherlands)
Back To table of contents
Teaching Lecture: Male Breast Cancer – Neglected Tumour Disease ■■ 08:00 - 08:45
Discussion and Roundup
Speaker: F. Otto (Switzerland)
Tuesday 27 September 2011
Scientific Symposium: How to Understand and to Reverse Drug Resistance in Metastatic Breast Cancer
Special Session: New Insights in Metastatic Processes ■■ 11:30 - 12:30 Chair: S.A. Eccles (United Kingdom) Growth Control and Cancer Metastasis Speaker: S.A. Eccles (United Kingdom)
■■ 09:00 - 11:00 Chair: J. Bergh (Sweden) Chair: F. Andre (France) Introduction Speaker: J. Bergh (Sweden)
Matrix Metalloproteases and Remodelling of the Extracellular Matrix Speaker: Z. Werb (USA)
Functional Genomic Approaches to the Dissection of Drug Resistance Mechanisms in Breast Cancer Speaker: C. Swanton (United Kingdom)
Intravital Imaging of Cancer Invasion and Resistance to Therapy Speaker: P. Friedl (The Netherlands)
Parp Inhibitors Sensitivity and Resistance Speaker: T. Helleday (United Kingdom)
Discussion and Roundup
10
Breast Cancer - Early and Advanced Disease
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
mTOR an Attractive Drug Target in Breast Cancer: How to Reverse Resistance to mTOR Inhibitors Speaker: J. Baselga (USA) Concluding Remarks Speaker: F. Andre (France)
Scientific Symposium: Breast Conservation in Young Women With Early Breast Cancer
Tuesday 27 September 2011 Teaching Lecture: Triple Negative Breast Cancer – How to Best Treat it and Prevent Relapse? ■■ 08:00 - 08:45 Speaker: A. Di Leo (Italy)
Special Session: Is the Biology of Metastatic Breast Cancer Similar to the Primary Breast Cancer? ■■ 11:30 - 12:30
■■ 14:45 - 16:45
Chair: I. Smith (United Kingdom)
Chair: U. Veronesi (Italy) Chair: L. Pierce (USA)
Receptors and HER-2 to New Status Primary to Metastatic Intra Patients Difference? Speaker: G. Viale (Italy)
Introduction Speaker: U. Veronesi (Italy) What Is the Role of Radiotherapy in Reducing Local Relapse Risk? Speaker: L. Pierce (USA) What Are the Sources of Local Relapse? Speaker: M. Bollet (France) What Are the Effects of Systemic Therapy in reducing Local Relapse Risk? Speaker: S. Aebi (Switzerland) Should Women under 35 Years Be Treated by Mastectomy? Speaker: U. Veronesi (Italy) Concluding Remarks Speaker: L. Pierce (USA)
Debate: This House Believes that Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer ■■ 17:00 - 18:00 Moderator: R. Bristow (Canada) Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer Speaker in Favour: J. Bergh (Sweden) Small Biology-Driven Trials Will NOT Substitute Large Randomised Clinical Trials in Breast Cancer Speaker Against: D.F. Hayes (USA) Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer Seconder in Favour: C. Sotiriou (Belgium) Small Biology-Driven Trials Will NOT Substitute Large Randomised Clinical Trials in Breast Cancer Seconder Against: M. Piccart (Belgium) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed their Opinion
Special Considerations in Surgery for Elderly Patients With Head and Neck Cancer Speaker: J.L. Lefebvre (France) Lack of Benefit of Intensified Treatment Strategies in Elderly Patients With Squamous Cell Head and Neck Cancer Speaker: L. Licitra (Italy)
Advance Programme
How to Reserve the Resistance to Trastuzumab Speaker: F. Andre (France)
The Importance of Geriatric Assessment Using the ‘Frailty Index’ among Patients With Head and Neck Cancer Treated With Radiotherapy: Toxicity and Quality of Life Speaker: H. Langendijk (The Netherlands) Concluding Remarks Speaker: V. Gregoire (Belgium)
Central Nervous System
Genomic Data on Metastatic Disease Speaker: C. Klein (Germany)
Sunday 25 September 2011
Should Biopsy Be Done in Each Patient With a Suspicion of Metastatic Relapse? Speaker: J. Bergh (Sweden)
Special Session: Endpoints in Clinical Trials
Discussion and Roundup
■■ 13:15 - 14:15 Chair: R. Grant (United Kingdom)
Cancer in the Older Patient
Monday 26 September 2011 Teaching Lecture: Geriatrics and Haematological Malignancies ■■ 08:00 - 08:45
MR-Response Criteria in Neurooncology Speaker: M. Bendszus (Germany) Endpoints for Phase II Trials Speaker: S. Chang (USA) Endpoints for Phase III Trials Speaker: M.J. van den Bent (The Netherlands) Discussion and Roundup
Monday 26 September 2011
Speaker: C. Thieblemont (France)
Special Session: Health Status in Screening in Elderly Patients – Is This the Way Forward? ■■ 13:15 - 14:15 Chair: J.P. Droz (France) Geriatric Evaluation Is the Principle Way of Assessing the Elderly Patients Speaker: R. Bernabei (Italy) The Use of Screening Tools in Geriatric Oncology Speaker: M. Extermann (USA) Discussion and Roundup
Tuesday 27 September 2011 Scientific Symposium: Head and Neck Cancer in the Elderly Patient ■■ 09:00 - 11:00 Chair: V. Gregoire (Belgium) Chair: H. Langendijk (The Netherlands) Introduction Speaker: H. Langendijk (The Netherlands) Epidemiology and the Practice of Treatment of the Elderly Patient in Head and Neck Cancer Speaker: K. Syrigos (Greece)
Teaching Lecture: Anaplastic Gliomas: An Emerging Entity ■■ 08:00 - 08:45 Speaker: W. Wick (Germany)
Scientific Symposium: Optimising Treatment in Gliomas ■■ 09:00 - 11:00 Chair: M. Hegi (Switzerland) Chair: O. Chinot (France) Introduction Speaker: O. Chinot (France) Molecular Biomarkers Speaker: C. Brennan (USA) Radiotherapy Speaker: M. Mehta (USA) Translational Speaker: R. Bjerkvig (Norway) Angiogenesis Speaker: R. Stupp (Switzerland) Clinical Speaker: O. Chinot (France) Concluding Remarks Speaker: M. Hegi (Switzerland)
Back To table of contents
11
Debate: This House Believes That Radiotherapy in Brain Metastases Does Matter ■■ 17:00 - 18:00 Moderator: W. Grisold (Austria) Radiotherapy in Brain Metastases Does Really Matter Speaker in Favour: B. Baumert (The Netherlands) Radiotherapy in Brain Metastases Does NOT Really Matter Speaker Against: R. Soffietti (Italy) Radiotherapy in Brain Metastases Does Really Matter Seconder in Favour: S. Short (United Kingdom) Radiotherapy in Brain Metastases Does NOT Really Matter Seconder Against: A.A. Brandes (Italy) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Diagnostic / Biomarkers
Monday 26 September 2011 Scientific Symposium: High Throughput Technology Platforms for Biomarker Discovery – State of the Art
Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer Seconder in Favour: J.C. Soria (France) Whole Genome Sequencing Will NOT Replace Conventional Histopathology in Diagnosis and Classification of Cancer Seconder Against: G. Viale (Italy) Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion
Drug Development
Full Genome Sequence Analysis Speaker: S. Aparicio (Canada) Integration of System Biology and Bioinformatics in Cancer Speaker: S.H. Friend (USA) Concluding Remarks Speaker: V. Lazar (France)
Debate: This House Believes That Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer ■■ 17:00 - 18:00 Moderator: M. Van de Vijver (The Netherlands) Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer Speaker in Favour: A.L. Børresen-Dale (Norway) Back To table of contents
Concluding Remarks Speaker: P. Workman (United Kingdom)
Special Session: Innovations in Early Clinical Trials ■■ 11:30 - 12:30 Chair: S. Marsoni (Italy) Phase O vs. Phase I - Ethics, Regs and Feasibility Speaker: A.J. Murgo (USA)
Tackling Futility With Adaptive Designs Speaker: M. Buyse (Belgium)
■■ 08:00 - 08:45
Discussion and Roundup
Speaker: C.N. Baxevanis (Greece)
Debate: This House Believes That Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug ■■ 17:00 - 18:00
Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug Speaker in Favour: J. Baselga (USA)
Proteomics Speaker: J. Lehtiö (Sweden)
PI3 Kinases Speaker: J. Tabernero (Spain)
Teaching Lecture: Status of Therapeutic Anticancer Vaccines
Chair: L. Pusztai (USA) Chair: V. Lazar (France)
Role of Gene Expression Profiling for Biomarker Discovery Speaker: L. Pusztai (USA)
MEK-RAF Inhibitors Speaker: D. Solit (USA)
Monday 26 September 2011
Moderator: E. Cohen-Jonathan-Moyal (France)
Overview and Definition of Biomarkers (General Introduction) Speaker: J. Reis-Filho (United Kingdom)
BRAF/KRAS Codrivers of Tumour Progression Speaker: R. Marais (United Kingdom)
Innovative Models to Optimise Phase I Development of Novel Anticancer Agents Speaker: J.H.M. Schellens (The Netherlands)
■■ 14:45 - 16:45
Introduction Speaker: L. Pusztai (USA)
12
Whole Genome Sequencing Will NOT Replace Conventional Histopathology in Diagnosis and Classification of Cancer Speaker Against: E. Brambilla (France)
Using Markers in Early Clinical Trials Does NOT Accelerate the Development Process of a New Drug Speaker Against: L. Gianni (Italy) Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug Seconder in Favour: D. Solit (USA) Using Markers in Early Clinical Trials Does NOT Accelerate the Development Process of a New Drug Seconder Against: M.J. Ratain (USA) Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion
Tuesday 27 September 2011 Scientific Symposium: Unravelling Ras PI3 Kinases Targets ■■ 09:00 - 11:00 Chair: S. Sleijfer (The Netherlands) Chair: P. Workman (United Kingdom) Introduction Speaker: S. Sleijfer (The Netherlands) Combinatorial Approaches Speaker: J.S. de Bono (United Kingdom)
Education
Saturday 24 September 2011 Teaching Lecture: Breast Cancer in the Elderly: Different Treatment Modalities ■■ 08:00 - 08:45 Speaker: R. Audisio (United Kingdom)
Teaching Lecture: Management of Local Recurrence of Rectal Cancer ■■ 08:00 - 08:45 Speaker: T. Wiggers (The Netherlands)
Teaching Lecture: Management of Early Non-Small Cell Lung Cancer ■■ 08:00 - 08:45 Speaker: T. Le Chevalier (France)
Teaching Lecture: What Are the Expected Developments in Medical Treatment of Bladder Cancer ■■ 08:00 - 08:45 Speaker: J. Bellmunt (Spain)
Teaching Lecture: Radiotherapy of Prostate Cancer ■■ 08:00 - 08:45 Speaker: V. Khoo (United Kingdom)
Teaching Lecture: The Current Treatment of Nasopharyngeal Cancer ■■ 08:00 - 08:45 Speaker: A.T. Chan (Hong Kong)
Teaching Lecture: To PET or Not to PET: What Are the Indications?
Teaching Lecture: Current Standards and New Trends in the Primary Treatment of Colorectal Cancer
Teaching Lecture: Diagnostic and Therapeutic Approach of Primary Cutaneous Lymphomas
■■ 08:00 - 08:45
■■ 08:00 - 08:45
Speaker: C. Bokemeyer (Germany)
Speaker: To Be Announced
Teaching Lecture: Advances in the Treatment of Myeloma
Teaching Lecture: Thymoma
■■ 08:00 - 08:45
■■ 08:00 - 08:45
Teaching Lecture: Current Approaches to Adjuvant Therapy of Melanoma
Speaker: M.A. Dimopoulos (Greece)
Speaker: P. Baas (The Netherlands)
■■ 08:00 - 08:45 Speaker: S. Stroobants (Belgium)
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
■■ 08:00 - 08:45 Speaker: S. Aamdal (Norway)
Teaching Lecture: Protein Homeostasis ■■ 08:00 - 08:45 Speaker: T. Jung (Germany)
Educational Symposium: Metastatic Breast Cancer: What Do the Different Treatment Modalities Add to Survival? ■■ 16:00 - 18:00 Chair: S.R.D. Johnston (United Kingdom) The Role of Surgery in Metastatic Breast Cancer Speaker: J. Ruiterkamp (The Netherlands) Radiotherapy in Patients With Metastatic Breast Cancer Speaker: W. Budach (Germany) The Role of Hormonal Manipulations in Patients With Hormone-Sensitive Metastatic Breast Cancer Speaker: M. Castiglione-Gertsch (Switzerland) The Role of Chemotherapy and Targeted Agents in Patients With Metastatic Breast Cancer Speaker: S.R.D. Johnston (United Kingdom)
Teaching Lecture: New Adjuvant Treatments for Locally Advanced Prostate Cancer ■■ 08:00 - 08:45
Teaching Lecture: Medulloblastoma ■■ 08:00 - 08:45 Speaker: L. Padovani (France)
Speaker: A. Horwich (United Kingdom)
Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 1): Basic Science of Lung Cancer ■■ 08:00 - 08:45 Speaker: H. Kristeleit (United Kingdom)
Teaching Lecture: Adjuvant Chemotherapy and Radiation Therapy in High Risk Penile Cancer ■■ 08:00 - 08:45 Speaker: C. Theodore (France)
Teaching Lecture: New Technology in Radiotherapy ■■ 08:00 - 08:45 Speaker: J. Kazmierska (Poland)
Educational Symposium: Optimal Treatment for Advanced Ovarian Cancer ■■ 14:45 - 16:45 Chair: I.B. Vergote (Belgium) Surgery: Primary or Neoadjuvant Therapy Speaker: I.B. Vergote (Belgium) First Line Therapy: Have We Made Any Improvement? Speaker: M. Bookman (USA) Optimal Treatment for Relapsed Disease Speaker: J. Ledermann (United Kingdom) The Role of Targeted Therapy in Ovarian Cancer Speaker: S.B. Kaye (United Kingdom)
Educational Symposium: Screening for Cancer: Sense and Sensibilities ■■ 14:45 - 16:45
Educational Symposium: The Jungle of Treatments in Advanced Colorectal Cancer
Teaching Lecture: Growth Factor Receptor Related Therapy for Gastric Cancer
■■ 16:00 - 18:00
■■ 08:00 - 08:45
Chair: C.J.H. van de Velde (The Netherlands) Conversion and Neoadjuvant Chemotherapy Speaker: G. Folprecht (Germany) Treatment of PS2 and Rapidly Progressive Disease Speaker: C. Verhoef (The Netherlands)
Speaker: A. Cervantes (Spain)
Teaching Lecture: Uterine Sarcomas: A Multidisciplinary Challenge ■■ 08:00 - 08:45 Speaker: P.G. Casali (Italy)
Chair: R.J. van Klaveren (The Netherlands) Breast Cancer Speaker: P. Autier (France) Lung Cancer Speaker: R.J. van Klaveren (The Netherlands) Colorectal Cancer Speaker: C. Masseria (United Kingdom) Prostate Cancer Speaker: F.H. Schroeder (The Netherlands)
Teaching Lecture: Thyroid – Emerging Tumours
Interactive Workshop: What Knowledge and Attitudes Do Paid Carers of People With Learning Disabilities Have About Cancer?
Re-Challenge and the Concept of the Number Lines Therapy Speaker: A. de Gramont (France)
■■ 08:00 - 08:45
■■ 15:00 - 16:00
Speaker: M. Schlumberger (France)
Coordinator: D.E. Wyatt (United Kingdom) Coordinator: P. Talbot (United Kingdom)
Sunday 25 September 2011
Teaching Lecture: DNA Repair as Treatment Target
The Treatment of Patients With Low Tumour Burden and/or Slow Growing Disease Speaker: T.S. Maughan (United Kingdom)
Teaching Lecture: How to Personalise Treatment in Early Breast Cancer ■■ 08:00 - 08:45 Speaker: T. Sørlie (Norway)
Monday 26 September 2011
■■ 08:00 - 08:45 Speaker: T. Helleday (United Kingdom)
Teaching Lecture: Male Breast Cancer – Neglected Tumour Disease ■■ 08:00 - 08:45 Speaker: F. Otto (Switzerland)
Back To table of contents
13
Teaching Lecture: Skin-Sparing Mastectomy
Teaching Lecture: Status of Therapeutic Anticancer Vaccines
■■ 08:00 - 08:45
■■ 08:00 - 08:45
Speaker: A.D. Baildam (United Kingdom)
Speaker: C.N. Baxevanis (Greece)
Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 3): Chemotherapy in Lung Cancer ■■ 08:00 - 08:45 Speaker: R. Lal (United Kingdom)
Interactive Session With Patient Cases: Stage IIIa Non-Small Cell Lung Cancer - Views by the Surgeon, Radiotherapist and Medical Oncologist
Teaching Lecture: Emergency and Palliative Care
■■ 08:00 - 09:00
Speaker: D. Schrijvers (Belgium)
Chair: G. Giaccone (USA) Presentation of a Complex Case Speaker: G. Giaccone (USA) Surgeon's Point of View Speaker: U. Pastorino (Italy) Radiotherapist's Point of View Speaker: D. Zips (Germany) Medical Oncologist's Point of View Speaker: B. Besse (France) Discussion and Roundup
Teaching Lecture: Radiation Therapy and Radioisotopes for Bone Metastases: What Is Their Real Benefit? ■■ 08:00 - 08:45 Speaker: U. Nestle (Germany)
Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 2): Epidemiology of Lung Cancer ■■ 08:00 - 08:45 Speaker: S.J. O'Connor (The Netherlands)
Teaching Lecture: Cancer and Pregnancy: What Should We Know About the Management With Systemic Treatment of Pregnant Women With Cancer? ■■ 08:00 - 08:45 Speaker: N. Pavlidis (Greece)
■■ 08:00 - 08:45
■■ 08:00 - 08:45
■■ 08:00 - 08:45 Speaker: J. Neoptolemos (United Kingdom)
Teaching Lecture: Geriatrics and Haematological Malignancies ■■ 08:00 - 08:45 Speaker: C. Thieblemont (France)
Teaching Lecture: Translational Genomics in Breast Cancer ■■ 08:00 - 08:45 Speaker: C. Caldas (United Kingdom)
Teaching Lecture: Ewing Sarcoma Treatment ■■ 08:00 - 08:45 Speaker: H.F. Jürgens (Germany)
Educational Symposium: Medical Treatment of Metastatic Prostate Cancer ■■ 14:45 - 16:45 Chair: B. Tombal (Belgium) What Is the Pathophysiology of a HormoneResistant Prostate Tumour? Speaker: B. Tombal (Belgium) Targeting the Androgen Receptor Speaker: J.S. de Bono (United Kingdom) Novel Treatments for Castration-Resistant Prostate Cancer Speaker: C.N. Sternberg (Italy) Experimental Models for Development of New Medical Treatments in Prostate Cancer Speaker: A. Chauchereau (France)
Interactive Workshop: Dealing With Emotionally Challenging Patients or Families ■■ 17:00 - 18:00
Teaching Lecture: Current Standards and New Trends in Esophageal Cancer
Teaching Lecture: Adjuvant Treatment of Pancreatic Cancer
Coordinator: L. Fallowfield (United Kingdom)
Teaching Lecture: Overview on the Role of Laparoscopic Surgery in Cancer Management ■■ 08:00 - 08:45 Speaker: P. Willemsen (Belgium)
Interactive Session With Patient Cases: A Patient With a T2N0M0 Prostate Cancer, Gleason Score 7, PSa 19 µg/L Views by the Urologist, Radiotherapist and Medical Oncologist ■■ 08:00 - 09:00 Chair: F.H. Schroeder (The Netherlands) Presentation of a Complex Case Speaker: F.H. Schroeder (The Netherlands) Urologist's Point of View Speaker: J. Hugosson (Sweden) Radiotherapist's Point of View Speaker: C. Parker (United Kingdom) Medical Oncologist's Point of View Speaker: J. Bellmunt (Spain) Discussion and Roundup
Teaching Lecture: Soft Tissue Sarcomas: Are All Soft Tissue Sarcomas Treated With the Same Drugs? ■■ 08:00 - 08:45
Tuesday 27 September 2011
Speaker: J.Y. Blay (France)
Teaching Lecture: Active Surveillance and Prostatectomy
Teaching Lecture: Triple Negative Breast Cancer – How to Best Treat It and Prevent Relapse?
■■ 08:00 - 08:45
■■ 08:00 - 08:45
Educational Symposium: 2010 Consensus on Lung Cancer: New Clinical Recommendations & Current Status of Biomarker Assessment
Speaker: C.H. Bangma (The Netherlands)
Speaker: A. Di Leo (Italy)
Teaching Lecture: Anaplastic Gliomas: An Emerging Entity
Teaching Lecture: Combining Molecular Targeted Agents and Radiotherapy
First Line Speaker: C. Gridelli (Italy)
■■ 08:00 - 08:45
■■ 08:00 - 08:45
Speaker: W. Wick (Germany)
Speaker: T. Brunner (United Kingdom)
Second Line Speaker: F. De Marinis (Italy)
Speaker: F. Lordick (Germany)
■■ 09:00 - 11:00 Chair: R. Stahel (Switzerland)
Early Locally Advanced Disease Speaker: W. Weder (Switzerland) SCLC Speaker: C. Le Pechoux (France)
14
Back To table of contents
Educational Symposium: Dealing With Children of Cancer Patients
Sunday 25 September 2011
Introduction Speaker: E. Van Cutsem (Belgium)
■■ 09:00 - 11:00
Special Session: Calories and Cancer
Chair: L.J. Hjorth (Sweden)
■■ 13:15 - 14:15
The Genomic and Stem Cell Perspective Speaker: I. Tomlinson (United Kingdom)
Paediatric Outcomes following in Utero Exposure to Treatment of Maternal Malignancy Speaker: I. Nulman (Canada)
Chair: A. Gescher (United Kingdom)
Cancer in Offspring of Cancer Patients: Genetic or Induced? Speaker: J.H. Olsen (Denmark) Psychological Impact of Having a Parent With Cancer Speaker: G. Huizinga (The Netherlands) Coping Mechanisms of Offspring of Cancer Patients and Can We Help Them? Speaker: M. Thastum (Denmark)
Body Mass Index and Cancer Incidence Speaker: A.G. Renehan (United Kingdom) Biochemical Consequence of Caloric Restriction Speaker: V.D. Longo (USA) Energy Balance Including Physical Activity Influence Breast and Colon Carcinogenesis Results From Recent Studies Speaker: I. Thune (Norway) Discussion and Roundup
Epidemiology, Primary and Secondary Prevention
Saturday 24 September 2011
Saturday 24 September 2011
Special Session: Preventing Cervical Cancer
Teaching Lecture: Management of Local Recurrence of Rectal Cancer
■■ 14:15 - 15:15
■■ 08:00 - 08:45
Chair: J. Dillner (Sweden)
Speaker: T. Wiggers (The Netherlands)
Cervix Cancer Vaccination Speaker: J. Cuzick (United Kingdom) Cervix Cancer Screening - European Guidelines Speaker: L. Von Karsa (France)
Educational Symposium: The Jungle of Treatments in Advanced Colorectal Cancer ■■ 16:00 - 18:00 Chair: C.J.H. van de Velde (The Netherlands)
Discussion and Roundup
Scientific Symposium: Molecular Cancer Epidemiology - the Next Generation
Treatment of PS2 and Rapidly Progressive Disease Speaker: C. Verhoef (The Netherlands)
Chair: C.P. Wild (France) Chair: P. Hall (Sweden) Introduction Speaker: C.P. Wild (France) Cancer Incidence and Mortality in Europe – GLOBOCAN 2008 Speaker: D. Forman (France) Genetic Susceptibility: Are We Surfing or Diving Genome? Speaker: P. Pharoah (United Kingdom) Are ‘Environmental Wide Association Studies’ (EWAS) the Missing Piece? Speaker: P. Vineis (United Kingdom) Epigenomics in Population Studies Speaker: M. Esteller (Spain) Concluding Remarks Speaker: P. Hall (Sweden)
Optimal Approach on the KRAS Wild Type Speaker: P. Rougier (France) Optimal Approach of the KRAS Mutant Speaker: E. Van Cutsem (Belgium) The Angiogenesis Inhibition Speaker: M. Dicato (Luxembourg) Concluding Remarks Speaker: P. Rougier (France)
Scientific Symposium: Tailored Neoadjuvant Therapy in Rectal Cancer ■■ 09:00 - 11:00
Conversion and Neoadjuvant Chemotherapy Speaker: G. Folprecht (Germany)
■■ 16:00 - 18:00
The Role of Microsatellite Instability in the Era of Personalised Medicine Speaker: E. Vilar (USA)
Monday 26 September 2011 Gastrointestinal Malignancies Colorectal Cancer
Prospects for Rapid Worldwide Reduction of Cervical Cancer Speaker: J. Peto (United Kingdom)
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
The Treatment of Patients With Low Tumour Burden and/or Slow Growing Disease Speaker: T.S. Maughan (United Kingdom) Re-Challenge and the Concept of the Number Lines Therapy Speaker: A. de Gramont (France)
Sunday 25 September 2011
Chair: V. Valentini (Italy) Chair: L. Påhlman (Sweden) Introduction Speaker: L. Påhlman (Sweden) Tailored Neoadjuvant Therapy According to Initial Staging Versus Biology Predictors Speaker: K. Haustermans (Belgium) Tailored Therapy During Neoadjuvant Treatment Speaker: V. Valentini (Italy) Tailored Surgery According to Clinical Response Speaker: J.G. Guillem (USA) Tailored Adjuvant Chemotherapy According to Pathological Response Speaker: W. Scheithauer (Austria) Tailored Follow-Up According to Staging Speaker: L. Påhlman (Sweden) Concluding Remarks Speaker: V. Valentini (Italy)
Debate: This House Believes That Transanal Endoscopic Microsurgery (TEM) / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation ■■ 17:00 - 18:00 Moderator: B. Glimelius (Sweden)
Teaching Lecture: Current Standards and New Trends in the Primary Treatment of Colorectal Cancer ■■ 08:00 - 08:45 Speaker: C. Bokemeyer (Germany)
Scientific Symposium: Tailored Chemotherapy in Colon Cancer ■■ 14:45 - 16:45 Chair: E. Van Cutsem (Belgium) Chair: P. Rougier (France)
TEM / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Speaker in Favour: C. Coco (Italy) TEM / no Surgery is NOT Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Speaker Against: C.J.H. van de Velde (The Netherlands) TEM / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Seconder in Favour: G. Lammering (The Netherlands) Back To table of contents
15
TEM / no Surgery is NOT Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Seconder Against: D. Sebag-Montefiore (United Kingdom) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Tuesday 27 September 2011 Special Session: Strategies of Prolonged Multimodality Treatment in Advanced Patients ■■ 11:30 - 12:30 Chair: H. Schmoll (Germany) Intermittent Treatment Speaker: A. de Gramont (France) Maintenance Treatment With Biologicals Speaker: J. Tabernero (Spain) Can We Consolidate Medical Response With Local Treatment Speaker: P. Rougier (France) Discussion and Roundup
Gastrointestinal Malignancies Non-Colorectal Cancer
Sunday 25 September 2011 Teaching Lecture: Growth Factor Receptor Related Therapy for Gastric Cancer ■■ 08:00 - 08:45 Speaker: A. Cervantes (Spain)
Scientific Co-Chair Speaker: A.L. Børresen-Dale (Norway)
Teaching Lecture: Adjuvant Treatment of Pancreatic Cancer
Scientific Co-Chair Speaker: J.C. Soria (France)
08:00 - 08:45 Speaker: J. Neoptolemos (United Kingdom)
Metabolism and Cancer Speaker: T.W. Mak (Canada)
Scientific Symposium: Hepatocellular Carcinoma: Novel Advancements in Diagnosis and Treatment
Individualised Medicine: Are We Hunting the Holy Grail? Personalised Medicine is the Future Speaker: J. Baselga (USA)
■■ 09:00 - 11:00 Chair: J. Llovet (Spain) Chair: V. Mazzaferro (Italy) Introduction Speaker: V. Mazzaferro (Italy) New Molecular Targeted Therapies Speaker: J. Llovet (Spain) Novel Imaging Techniques and Treatment Assessment for Evaluating Benefit From Targeted Agents Speaker: V. Vilgrain (France) Local Therapy for HCC Speaker: E. Lartigau (France) Liver Transplantation and Resection for HCC Speaker: V. Mazzaferro (Italy) Concluding Remarks Speaker: J. Llovet (Spain)
Debate: This House Believes That Chemotherapy Has No Further Role in the Treatment of Well Differentiated Neuroendocrine Tumours (NET)
Limitations to Individualised Medicine Speaker: To Be Announced
Presidential Session I: Best and Late Breaking Abstracts ■■ 13:45 - 15:45 Late Breaking and Best Abstracts
Sunday 25 September 2011 Scientific Symposium: Multidisciplinary Quality Assurance 09:00 - 11:00 Chair: M. Baumann (Germany) Introduction Speaker: M. Baumann (Germany) Quality Assurance of Oral Compliance Speaker: K. Meier (Germany) Quality Assurance of Surgery Speaker: C.J.H. van de Velde (The Netherlands)
■■ 11:30 - 12:30
Quality Assurance of Radiotherapy Speaker: J. Bernier (Switzerland)
Moderator: D. Cunningham (United Kingdom)
Concluding Remarks
Chemotherapy Has No Role Speaker in Favour: B. Wiedenmann (Germany) Chemotherapy Has a Role Speaker Against: T. Meyer (United Kingdom)
Keynote Lecture: Do We Still Need to Understand the Cancer Genome? ■■ 11:30 - 12:15
Monday 26 September 2011
Chemotherapy Has No Role Seconder in Favour: E. Raymond (France)
Speaker: M. Stratton (United Kingdom)
Teaching Lecture: Current Standards and New Trends in Esophageal Cancer
Chemotherapy Has a Role Seconder Against: M. Caplin (United Kingdom)
Presidential Session II: Best and Late Breaking Abstracts
■■ 08:00 - 08:45
Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion
■■ 12:30 - 14:30
Speaker: F. Lordick (Germany)
Special Session: Management of Hilar and Intrahepatic Cholangiocarcinoma ■■ 13:15 - 14:15 Chair: R. Adam (France) Surgical Resection of Hilar and Intrahematic Cholangiocarcinoma Speaker: O. Farges (France) Liver Transplantation for Cholangiocarcinoma Speaker: S. Jonas (Germany)
16
Tuesday 27 September 2011
Hamilton - Fairley Award Lecture
General
Saturday 24 September 2011
Late breaking and Best Abstracts
Scientific Symposium: ECCO/ASCO Scientific Symposium ■■ 14:45 - 16:45
Opening Session ■■ 09:00 - 11:00
Session: To Be Announced
09:00 - Welcome Speaker: M. Baumann (Germany)
Society session: European Society for Medical Oncology (ESMO) Awards Session
Adjuvant and Systemic Treatment of Advanced Cholangiocarcinoma Speaker: J. Valle (United Kingdom)
ESMO Welcome Speaker: D. Kerr (United Kingdom)
Discussion and Roundup
ESTRO Welcome Speaker: J. Bourhis (France)
Back To table of contents
ECCO - Pezcoller Award Lecture
■■ 16:45 - 18:15 Chair: D. Kerr (United Kingdom)
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
ESMO Lifetime Achievement Award ESMO 2010 Best Examination Award ESMO Palliative Care Designated Centre Accreditation ESMO Fellowship Programme and Awards Speakers: To Be Announced
Society Session: European Society for Therapeutic Radiology and Oncology (ESTRO) ■■ 16:45 - 18:15 Chair: J. Bourhis (France) The Klaas Breur Award Lecture Speaker: B. Wouters (Canada) Emmanuel Van Der Schueren Lecture Speaker: F.A. Calvo (Spain) Honorary Member Awardee Speaker: C. Perez (USA) Honorary Member Awardee Speaker: R. Bristow (Canada)
Society Session: European Oncology Nursing Society (EONS) - Couples - (the Prostate Cancer Charity) ■■ 16:45 - 18:15 Theatre/role Play on Prostate Cancer This Special Society Session will explore the project COUPLES. This was a unique artistic project between Professor Daniel Kelly (a member of the EONS Executive Board since 2007), the photographer Tim Wainwright, as well as a musician, a hospital arts co-ordinator and a theatre director. The project was funded by the 2008 Jeremy Gambrill Award and explores the impact of Prostate Cancer on various couples using photography, sound and extracts from interviews. Outcomes have included a specially designed website, a theatrical performance in London and a DVD. COUPLES explores the private impact of prostate cancer in a moving and challenging format. Daniel Kelly will present extracts from the project and the implications for using the Arts more widely as a vehicle to share the impact and experience of cancer.
Society Session: European Association of Urology (EAU) ■■ 16:45 - 18:15 Chair: M. Wirth (Germany) The Role of Screening in Prostate Cancer Speaker: F.H. Schröder (The Netherlands) Radical Prostatectomy - The Gold Standard in the Treatment of Localised and Locally Advanced Prostate Cancer Speaker: M. Wirth (Germany) Cystectomy and Urinary Diversion Lessons Learned Speaker: H. van Poppel (Belgium) Treatment of Small Renal Tumours, Surveillance Focal Treatment or Surgery Speaker: M. Marberger (Austria)
The EAU Guidelines on Testicular Cancer Speaker: M.P. Laguna (The Netherlands) What Is New in the Systemic Treatment of Urological Malignancies Speaker: P. Abrahamsson (Sweden)
Society Session: European Society of Surgical Oncology (ESSO) - Tailored Treatment for Older Cancer Patients - A Multidisciplinary Approach ■■ 16:45 - 18:15 Chair: P. Naredi (Sweden) The ESSO Award Presented to Ricardo Audisio Award Lecturer: R.A. Audisio (United Kingdom)
Society Session: Flims Alumni Club (FAC) ■■ 16:45 - 18:15 Chair: To Be Announced Chair: To Be Announced Introduction Speaker: To Be Announced How to Submit a Good Application? Speaker: To Be Announced Presentation of a Flims Study The Flims Alumni Club Speaker: To Be Announced The FAC Achievement Award Lecture Award Lecturer: To Be Announced Questions and Answers
Where and Why we Fail to Offer Appropriate Treatment to Older Cancer Patients Speaker: M. Jansen-Heijnen (The Netherlands)
Concluding Remarks Speaker: To Be Announced
Multimodal Tailored Treatment to Older Rectal Cancer Patients Speaker: H.J. Rutten (The Netherlands)
Society Session: European Association of Nuclear Medicine (EANM)
Cancer Clinical Trials in the Elderly: Are We Ageist? Speaker: B. Nordlinger (France) General Discussion Speaker: R.A. Audisio (United Kingdom)
Society Session: European Society of Gynaecological Oncology (ESGO)
Advance Programme
ESMO Award
■■ 16:45 - 18:15 Session: To Be Announced
Society Session: European Society of Oncology Pharmacy (ESOP) ■■ 16:45 - 18:15 Session: To Be Announced
■■ 16:45 - 18:15 Session: To Be Announced
Society Session: European Society of Breast Cancer Specialists (EUSOMA) ■■ 16:45 - 18:15 Age and Breast Cancer Discussant: B. Cutuli (France) The impact of age on breast cancer survival Speaker: A. Micheli (Italy) Age, screening and high risk groups surveillance Speaker: R. Wilson (UK) Eusoma Recommendations for the management of elderly women Speaker: L. Biganzoli (Italy) Eusoma Recommendations for the management of young women Speaker: F. Cardoso (Portugal) Discussion
Society Session: European Association of Neuro-Oncology (EANO) ■■ 16:45 - 18:15 The EANO Award presented to Kathy Oliver Chair: W. Grisold (Austria) New Entities in Paraneoplastic Diseases Speaker: A. Vincent (United Kingdom) How to Improve the Extent of Surgery With Better Neurological Function Preservation Speaker: L. Bello (Italy) Quality of Life and Cognitive Function Monitoring Speaker: M. Klein (The Netherlands) Stem Cells in Brain Tumours : Where Are We Going? Speaker: R. De Maria (Italy)
Society Session: The European Society for Paediatric Oncology (SIOP Europe) ■■ 16:45 - 18:15
Society Session: European Association for Cancer Research (EACR) ■■ 16:45 - 18:15 Chair J. Celis, (Denmark) EACR Researcher Award Winner Speaker to be announced From Genes to Drugs Speaker: N. Ferrara, (USA)
Proffered Paper Abstracts Will Be Presented in This Session
Society Session: European School of Oncology (ESO) ■■ 16:45 - 18:15 Session: To Be Announced
Tumour Suppressor Network Speaker M. Oren, (Israel) Back To table of contents
17
Monday 26 September 2011
Scientific Symposium: Diabetes, Obesity and Cancer
Sunday 25 September 2011
Scientific Symposium: ESMO Clinical Practice Guidelines
■■ 14:45 - 16:45
■■ 09:00 - 11:00
Session: To Be Announced
Teaching Lecture: Adjuvant Chemotherapy and Radiation Therapy in High Risk Penile Cancer
Introduction and ESMO Questionnaire by Session Chairs Chair: A. Cervantes (Spain) Chair: N. Pavlidis (Greece)
Tuesday 27 September 2011 Presidential Session IV: Best and Late Breaking Abstracts
Bladder Cancer Presentation Speaker: To Be Announced
■■ 09:00 - 11:00
Bladder Cancer Discussion Speaker: To Be Announced
Policy Makers Lecture Speaker: To Be Announced
Colorectal Cancer Presentation Speaker: To Be Announced
Late Breaking and Best Abstracts
Colorectal Cancer Discussion Speaker: To Be Announced Melanoma Presentation Speaker: To Be Announced
Genitourinary Malignancies - Other
Melanoma Discussion Speaker: To Be Announced
Saturday 24 September 2011
Conclusions by Session Chairs
Teaching Lecture: What Are the Expected Developments in Medical Treatment of Bladder Cancer
Keynote Lecture: How Registry Data Has Changed Rectal Cancer Treatment ■■ 11:30 - 12:15
■■ 08:00 - 08:45 Speaker: J. Bellmunt (Spain)
Speaker: L. Påhlman (Sweden)
Presidential Session III: Best and Late Breaking Abstracts ■■ 12:30 - 14:30 Policy Makers Lecture Speaker: To Be Announced Late Breaking and Best Abstracts
Scientific Symposium: ESMO-JSMO Joint Symposium - What Can We Learn From Global Clinical Trials?
Special Session: The Management of Penile Cancer ■■ 14:15 - 15:15 Chair: A. Kiltie (United Kingdom) Update in Penile Cancer: Facts Speaker: C.J.L.M. (The Netherlands) Surgery Speaker: E. Solsona (Spain) Chemotherapy Speaker: M. De Santis (Austria) Discussion and Roundup
■■ 14:45 - 16:45 Introduction by Session Chairs Chair: D. Kerr (United Kingdom) Chair: K. Tamura (Japan) Indox: Building a Collaborative Trials Network in India Speaker: D. Kerr (United kingdom) Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer Speaker: I. Okamoto (Japan) Lessons from Global Clinical Trials for Gastric Cancer: Are They Steps Ahead? Speaker: A. Ohtsu (Japan) Industry-Led Global Trials - Do Benefits Outweigh Pitfalls? Speaker: S.J. Horning (USA) Conclusions by Sesson Chairs
Scientific Symposium: New Insights in the Management of Renal Cancer ■■ 16:00 - 18:00 Chair: S. Oudard (France) Chair: P. Hoskin (United Kingdom) Introduction Speaker: S. Oudard (France) Genetics of Clear Cell Renal Carcinoma Speaker: W.G. Kaelin, Jr (USA) Pharmaco-Economics Speaker: P. Clark (United Kingdom) New Approaches in Surgical Management of Renal Cancer Speaker: Z. Kirkali (Turkey) How to Integrate New Imaging Modalities Speaker: L. Fournier (France) New Agents in Renal Cancer Speaker: B. Escudier (France) Concluding Remarks Speaker: P. Hoskin (United Kingdom)
18
Back To table of contents
■■ 08:00 - 08:45 Speaker: C. Theodore (France)
Special Session: Current Issues in the Management of Germ Cell Tumours ■■ 13:15 - 14:15 Chair: M. De Santis (Austria) Relapse and Prognostic Factors Speaker: J. Beyer (Germany) Novel Targets and New Treatment Speaker: D.R. Feldman (USA) Cancer Survivorship Speaker: J. Oldenburg (Norway) Discussion and Roundup
Debate: This House Believes That Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer ■■ 15:00 - 16:00 Moderator: J. Bellmunt (Spain) Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer Speaker in Favour: M. Wirth (Germany) Surgery Is NOT the Mainstay for the Treatment of PT2 Bladder Cancer Speaker Against: A.L. Zietman (USA) Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer Seconder in Favour: A.R. Zlotta (Canada) Surgery Is NOT the Mainstay for the Treatment of PT2 Bladder Cancer Seconder Against: A. Kiltie (United Kingdom) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Sunday 25 September 2011 Teaching Lecture: New Adjuvant Treatments for Locally Advanced Prostate Cancer ■■ 08:00 - 08:45
What Is the Pathophysiology of a Hormone-resistant Prostate Tumour? Speaker: B. Tombal (Belgium) Targeting the Androgen Receptor Speaker: J.S. de Bono (United Kingdom) Novel Treatments for Castration-Resistant Prostate Cancer Speaker: C.N. Sternberg (Italy) Experimental Models for Development of New Medical Treatments in Prostate Cancer Speaker: A. Chauchereau (France)
Speaker: A. Horwich (United Kingdom)
Monday 26 September 2011 Teaching Lecture: Active Surveillance and Prostatectomy ■■ 08:00 - 08:45 Speaker: C.H. Bangma (The Netherlands)
Scientific Symposium: From New Targets to New Drugs in Prostate Cancer ■■ 09:00 - 11:00 Chair: J. Bellmunt (Spain) Chair: N. Clarke (United Kingdom) Introduction Speaker: J. Bellmunt (Spain) Bone Targeting Speaker: K. Fizazi (France) Androgen Receptor Speaker: J. Bellmunt (Spain) New Chemotherapy Agents Speaker: O. Sartor (USA) Other Targets Speaker: K.N. Chi (Canada) Concluding Remarks Speaker: N. Clarke (United Kingdom)
Special Session: How Should We Treat Good Risk Prostate Cancer - Focally or Entirely? ■■ 13:15 - 14:15 Chair: T. de Reijke (The Netherlands) Active Surveillance Speaker: T. de Reijke (The Netherlands)
Sunday 25 September 2011 Teaching Lecture: Uterine Sarcomas: A Multidisciplinary Challenge ■■ 08:00 - 08:45 Speaker: P.G. Casali (Italy) Educational Symposium: Optimal Treatment for Advanced Ovarian Cancer
■■ 14:45 - 16:45 Debate: This House Believes That the Combination of Multi-Modality Treatment Is the Best Approach for the Treatment of High-Risk Prostate Cancer ■■ 17:00 - 18:00 Moderator: A. Bossi (France) The Combination of Multi-Modality Treatment Is the Best Approach for the Treatment of High-Risk Prostate Cancer Speaker in Favour: C.N. Sternberg (Italy) The Combination of Multi-Modality Treatment Is NOT the Best Approach for the Treatment of High-Risk Prostate Cancer Speaker Against: A. Heidenreich (Germany) The Combination of Multi-Modality Treatment Is the Best Approach for the Treatment of High-Risk Prostate Cancer Seconder in Favour: B. Tombal (Belgium) The Combination of Multi-Modality Treatment Is NOT the Best Approach for the Treatment of High-Risk Prostate Cancer Seconder Against: C. Parker (United Kingdom) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Tuesday 27 September 2011 Interactive Session With Patient Cases: A Patient With a T2N0M0 Prostate Cancer, Gleason Score 7, PSa 19 µg/L Views by the Urologist, Radiotherapist and Medical Oncologist ■■ 08:00 - 09:00 Chair: F.H. Schroeder (The Netherlands)
Brachytherapy - High Dose Rate or I-125? Speaker: P. Hoskin (United Kingdom)
Presentation of a Complex Case Speaker: F.H. Schroeder (The Netherlands)
Heat, Ice and Light Speaker: M. Emberton (United Kingdom)
Urologist's Point of View Speaker: J. Hugosson (Sweden)
Discussion and Roundup
Radiotherapist's Point of View Speaker: D.P. Dearnaley (United Kingdom)
Educational Symposium: Medical Treatment of Metastatic Prostate Cancer
Medical Oncologist's Point of View Speaker: To Be Announced
■■ 14:45 - 16:45
Gynaecological Cancer
Advance Programme
Genitourinary Malignancies Prostate Cancer
Discussion and Roundup
Chair: I.B. Vergote (Belgium) Surgery: Primary or Neoadjuvant Therapy Speaker: I.B. Vergote (Belgium) First Line Therapy: Have We Made Any Improvement? Speaker: M. Bookman (USA) Optimal Treatment for Relapsed Disease Speaker: J. Ledermann (United Kingdom) The Role of Targeted Therapy in Ovarian Cancer Speaker: S.B. Kaye (United Kingdom)
Monday 26 September 2011 Teaching Lecture: Cancer and Pregnancy: What Should We Know About the Management With Systemic Treatment of Pregnant Women With Cancer? ■■ 08:00 - 08:45 Speaker: N. Pavlidis (Greece)
Special Session: Controversies in the Management of Cervical Cancer ■■ 13:15 - 14:15 Chair: P. Morice (France) Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Speaker: N. Colombo (Italy) Image-guided Brachytherapy and External Radiotherapy Speaker: C. Haie-Méder (France) Management Aimed at Fertility Preservation Speaker: F. Amant (Belgium) Discussion and Roundup
Tuesday 27 September 2011 Scientific Symposium: From Bench to Bedside in Ovarian Cancer ■■ 09:00 - 11:00 Chair: S.B. Kaye (United Kingdom) Chair: M. d'Incalci (Italy)
Chair: B. Tombal (Belgium)
Back To table of contents
19
Introduction Speaker: S.B. Kaye (United Kingdom) New Concepts on the Origins of Ovarian Cancer Speaker: J. Prat (Spain) Genomics of Ovarian Cancer – Utility as Predictive Biomarkers Speaker: D. Huntsman (Canada)
PET-Guided Radiation Treatment Planning in Hodgkin Lymphoma Speaker: T. Girinsky (France) PET-Response Adapted Therapy in Hodgkin Lymphoma Speaker: C. Kobe (Germany) Discussion and Roundup
New Directions in Angiogenesis Therapy Speaker: G. Jayson (United Kingdom)
Scientific Symposium: Role of the Microenvironment in Lymphomas
Update on Targeted Therapies in Ovarian Cancer Speaker: C. Sessa (Switzerland)
■■ 16:00 - 18:00
Concluding Remarks Speaker: M. d'Incalci (Italy)
Debate: This House Believes That Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer ■■ 11:30 - 12:30 Moderator: S.B. Kaye (United Kingdom) Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer Speaker in Favour: I.B. Vergote (Belgium) Neoadjuvant Chemotherapy Should NOT Become Standard of Care in Ovarian Cancer Speaker Against: A. du Bois (Germany) Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer Seconder in Favour: L. Ungar (Hungary) Neoadjuvant Chemotherapy Should NOT Become Standard of Care in Ovarian Cancer Seconder Against: P. Morice (France) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Chair: P. Ghia (Italy) Chair: R. Küppers (Germany) Introduction Speaker: R. Küppers (Germany) The Microenvironment in B Cell Malignancies: a New Target for Therapy? Speaker: P. Ghia (Italy) The Stromal Cell Niche in Folliclar Lymphoma Speaker: K. Tarte (France) Clinical Relevance of the Microenvironment in Hodgkin Lymphoma Speaker: C. Steidl (Canada) Impact of the Tumor Microenvironment on Prognosis in Follicular Lymphoma Speaker: D. de Jong (The Netherlands) Concluding Remarks Speaker: P. Ghia (Italy)
Sunday 25 September 2011 Teaching Lecture: Diagnostic and Therapeutic Approach of Primary Cutaneous Lymphomas ■■ 08:00 - 08:45 Speaker: To Be Announced
Monday 26 September 2011 Debate: This House Believes That EPO Should Be Part of Daily Cancer Management ■■ 17:00 - 18:00 Moderator: J. Overgaard (Denmark) EPO Should Be Part of Daily Cancer Management Speaker in Favour: A. Engert (Germany) EPO Should NOT Be Part of Daily Cancer Management Speaker Against: O. Hermine (France) EPO Should Be Part of Daily Cancer Management Seconder in Favour: M. Aapro (Switzerland) EPO Should NOT Be Part of Daily Cancer Management Seconder Against: M. Dicato (Luxembourg) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Head and Neck Cancer
Saturday 24 September 2011 Teaching Lecture: The Current Treatment of Nasopharyngeal Cancer ■■ 08:00 - 08:45 Speaker: A.T. Chan (Hong Kong)
Special Session: Late Toxicity Treatment of Head and Neck Cancer ■■ 14:15 - 15:15 Chair: S. Subramanian (Russian Federation)
Haematological Malignancies and Myeloma
Saturday 24 September 2011 Teaching Lecture: Advances in the Treatment of Myeloma ■■ 08:00 - 08:45 Speaker: M.A. Dimopoulos (Greece)
Special Session: PET-Based Treatment Decisions in Hodgkin Lymphoma ■■ 14:15 - 15:15 Chair: T. Girinsky (France) FDG-PET in Hodgkin Lymphoma Speaker: M. Hutchings (Denmark)
20
Back To table of contents
Scientific Symposium: Molecular Genetics in Lymphoma - Current Knowledge and New Insights From High-Throughput Technologies
Biological Insights Speaker: R. Coppes (The Netherlands)
■■ 09:00 - 11:00
Late Functional Outcome in ChemoRadiation Speaker: H. Langendijk (The Netherlands)
Chair: B. Coiffier (France) Chair: V. Ribrag (France)
Late Functional Outcome Surgery Speaker: A. Dietz (Germany)
Introduction Speaker: B. Coiffier (France)
Discussion and Roundup
Chronic Lymphocytic Leukaemia (CLL) Speaker: T. Zenz (Germany)
Scientific Symposium: Head and Neck: What Next in Biologically Targeted Therapy?
Mantle Cell Lymphoma (MCL) Speaker: B. Coiffier (France)
■■ 16:00 - 18:00
Diffuse Large Cell Lymphoma (DLCL) Speaker: A. Rosenwald (Germany)
Chair: K. Harrington (United Kingdom) Chair: J.B. Vermorken (Belgium)
Follicular Lymphoma Speaker: J. Fitzgibbon (United Kingdom)
Introduction Speaker: J.B. Vermorken (Belgium)
Concluding Remarks Speaker: V. Ribrag (France)
Stem Cells in Head and Neck Cancer Speaker: D. Zips (Germany)
New Targeted Drugs - Biological Agents Speaker: K. Harrington (United Kingdom)
Introduction Speaker: R. Blasberg (USA)
Monday 26 September 2011
Management Based on Results of Functional Imaging Speaker: K. Newbold (United Kingdom)
Imaging of Hypoxia With PET Radiotracers, Including, Ca-IX Antibodies Speaker: H. Schöder (USA)
Targeted Agents in Salivary Gland Tumours Speaker: L.L. Siu (Canada)
Interest of Functional Imaging to Guide Steriotactic Radiotherapy Speaker: E. Lartigau (France)
Scientific Symposium: Challenges and Opportunities in the Development of Targeted Therapies: Perspectives from the Therapeutics and Diagnostics Industries
Concluding Remarks Speaker: K. Harrington (United Kingdom)
Sunday 25 September 2011 Teaching Lecture: Thyroid – Emerging Tumours ■■ 08:00 - 08:45
Imaging of Hypoxia With Genetically Encoded Reporter Genes Speaker: R. Blasberg (USA) Application of Hypoxia Imaging in Radiation Treatment Planning Speaker: U. Nestle (Germany) Concluding Remarks Speaker: E. Lartigau (France)
Speaker: M. Schlumberger (France)
Debate: This House Believes That Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours ■■ 13:15 - 14:15 Moderator: J.B. Vermorken (Belgium) Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours Speaker in Favour: M.L. Gillison (USA) Patients With HPV+ve Tumours Should NOT Be Managed Differently From Those With HPV-ve Tumours Speaker Against: H. Mehanna (United Kingdom) Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours Seconder in Favour: J.-P. Klussmann (Germany) Patients With HPV+ve Tumours Should NOT Be Managed Differently From Those With HPV-ve Tumours Seconder Against: L. Licitra (Italy) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Imaging
Saturday 24 September 2011 Teaching Lecture: To PET or Not to PET: What Are the Indications? ■■ 08:00 - 08:45 Speaker: S. Stroobants (Belgium)
Scientific Symposium: Molecular Imaging of Hypoxia ■■ 11:15 - 13:15 Chair: R. Blasberg (USA) Chair: E. Lartigau (France)
Special Session: Monitoring Tumour Response to Therapy - What Do the Images Tell Us? ■■ 14:15 - 15:15 Chair: V. Vilgrain (France) PET/CT for Tumour Response Assessment Speaker: S. Stroobants (Belgium) Functional MRI of Therapy Response Speaker: A.R. Padhani (United Kingdom) DCI - Ultrasound Speaker: N. Lassau (France) Discussion and Roundup
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
■■ 14:45-16:45 Chair: D. Chang (USA) Chair: A. Riva (USA) Experiences in the development of targeted therapies Speaker: To Be Announced Strategies, Experiences, and Challenges in the Development of Companion Diagnostics Speaker: D. Parkinson (USA) Registration-directed co-development of biomarkers and therapeutics Speaker To Be Announced
Special Session:Co-development of investigational agents: industry experience and perspective ■■ 17:00-18:00 Chair: G. Saeter (Norway) Scientific rational Speaker To Be Announced Practical aspects Speaker To Be Announced Regulatory perspective Speaker To Be Announced
Industry Track
Panel discussion
Sunday 25 September 2011
Lung Cancer- Early and Metastatic
Scientific Symposium: The Role of Medical Technology in Building a Sustainable Cancer Care ■■ 14:45 - 16:45 How Medical Technologies and Pharmaceutical Industry Can Work Together Speaker: To Be Announced
Saturday 24 September 2011 Teaching Lecture: Management of Early Non-Small Cell Lung Cancer 08:00 - 08:45 Speaker: T. Le Chevalier (France)
IT Enabled Clinical Decision Support and Integration of Cancer Care-Role of EMR and Cancer Registries Speaker: To Be Announced
Scientific Symposium: Optimal Treatment for a 72-Year-Old Patient With Stage III-N2 Non-Small Cell Lung Cancer
Molecular Diagnostics Role in Personalised Cancer Care Speaker: To Be Announced
■■ 16:00 - 18:00
The Future of Radiation Therapy in Comprehensive Cancer Care Speaker: To Be Announced
Chair: D. De Ruysscher (The Netherlands) Chair: P.A. Kosmidis (Switzerland) Introduction Speaker: P.A. Kosmidis (Switzerland) Stage III-N2 Non-Small Cell Lung Cancer: Identifying Patients Subgroups and the Need to Tailor Therapy Speaker: K. O'Byrne (Ireland) Evidence to Support Definitive ChemoRadiotherapy Speaker: D. De Ruysscher (The Netherlands)
Back To table of contents
21
Evidence to Support Use of Planned Surgery Speaker: P. De Leyn (Belgium) Stage III-N2 Non-Small Cell Lung Cancer: Choice of Chemotherapy Schemes Speaker: E. Felip Font (Spain)
Melanoma and Skin Cancer
Does Surgery Improve Outcome? Speaker: U. Pastorino (Italy)
Saturday 24 September 2011
Concluding Remarks Speaker: D. De Ruysscher (The Netherlands)
Concluding Remarks Speaker: E. Felip Font (Spain)
Sunday 25 September 2011
Debate: This House Believes That Maintenance Therapy Is Standard of Care in Non-Small Cell Lung Cancer
Teaching Lecture: Thymoma
■■ 08:00 - 08:45 Speaker: P. Baas (The Netherlands)
Special Session: Novel Targeted Therapies for Metastatic Non-Small Cell Lung Cancer ■■ 15:00 - 16:00 Chair: R. Dziadziuszko (Poland) ALK Inhibitors Speaker: D.R. Camidge (USA) IGF1R Inhibitors Speaker: L. Paz Ares (Spain) Other Molecular Targets Speaker: J.C. Soria (France) Discussion and Roundup
Monday 26 September 2011
■■ 17:00 - 18:00 Moderator: T. Le Chevalier (France) Maintenance Therapy Is Standard of Care in Non-Small Cell Lung Cancer Speaker in Favour: F. Cappuzzo (Italy) Maintenance Therapy Is NOT Standard of Care in Non-Small Cell Lung Cancer Speaker Against: H. Groen (The Netherlands) Maintenance Therapy Is Standard of Care in Non-Small Cell Lung Cancer Seconder in Favour: P.M. Fidias (USA) Maintenance Therapy Is NOT Standard of Care in Non-Small Cell Lung Cancer Seconder Against: G. Scagliotti (Italy) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Special Session: Too Little or Too Much Surgery for Melanoma ■■ 14:15 - 15:15 Chair: A. Testori (Italy) For Sentinel Node Positive Patients: Is Complete Lymph Node Resection Still the Standard? Speaker: O. Nieweg (The Netherlands) For Patients With Distant Metastases: Surgery Is First Choice of Treatment Speaker: S. Schneebaum (Israel) A Critical View: Selection Is the Standard Speaker: A.M.M. Eggermont (The Netherlands) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Scientific Symposium: Melanoma Realising the Potential in Immunotherapy ■■ 16:00 - 18:00 Chair: A.M.M. Eggermont (The Netherlands) Chair: L. Zitvogel (France)
Tuesday 27 September 2011
Introduction Speaker: A.M.M. Eggermont (The Netherlands) Current Insights in Mechanism of Action of Anti-CTLA4 Speaker: J.P. Allison (USA)
■■ 08:00 - 09:00
Educational Symposium: 2010 Consensus on Lung Cancer: New Clinical Recommendations & Current Status of Biomarker Assessment
Chair: G. Giaccone (USA)
■■ 09:00 - 11:00
Presentation of a Complex Case Speaker: G. Giaccone (USA)
Chair: R. Stahel (Switzerland)
Interactive Session With Patient Cases: Stage IIIa Non-Small Cell Lung Cancer Views by the Surgeon, Radiotherapist and Medical Oncologist
Surgeon's Point of View Speaker: U. Pastorino (Italy) Radiotherapist's Point of View Speaker: D. Zips (Germany) Medical Oncologist's Point of View Speaker: B. Besse (France) Discussion and Roundup
Scientific Symposium: Non-Small Cell Lung Cancer - Advanced Disease ■■ 09:00 - 11:00 Chair: C. Faivre-Finn (United Kingdom) Chair: E. Felip Font (Spain) Introduction Speaker: C. Faivre-Finn (United Kingdom) The Challenge of Assessing and Targeting Tumour Hypoxia in Non-Small Cell Lung Cancer Speaker: Q.T. Le (USA) Intensity Modulated Radiotherapy: Fixed-Beam and Arc Delivery Techniques for Locally Advanced Disease Speaker: S. Senan (The Netherlands)
22
Integrating Systemic and Radiation Therapy in Locally Advanced Tumours Speaker: A. Price (United Kingdom)
Back To table of contents
First Line Speaker: C. Gridelli (Italy) Second Line Speaker: F. De Marinis (Italy) Early Locally Advanced Disease Speaker: W. Weder (Switzerland) Small Cell Lung Cancer Speaker: C. Le Pechoux (France)
Special Session: Treatment of T1N0M0 Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Lobectomy ■■ 11:30 - 12:30 Chair: P. Dartevelle (France) Alternative Surgical Resections for Lobectomy Speaker: P. Dartevelle (France) Role of Stereotactic Radiotherapy Speaker: M. Guckenberger (Germany) Role of Radio-Frequency Ablation Speaker: T. de Baere (France) Discussion and Roundup
Can Chemotherapeutics Synergise With Anti-CTLA4? Speaker: L. Zitvogel (France) Update Anti-CTLA in First Line and Second Line Therapy Speaker: J. Wolchok (USA) Combination Strategies Speaker: J.S. Weber (USA) Concluding Remarks Speaker: L. Zitvogel (France)
Sunday 25 September 2011 Teaching Lecture: Current Approaches to Adjuvant Therapy of Melanoma ■■ 08:00 - 08:45 Speaker: S. Aamdal (Norway)
Scientific Symposium: Melanoma Therapy - Realising the Potential in Targeted Therapy ■■ 09:00 - 11:00 Chair: R. Marais (United Kingdom) Chair: C. Robert (France)
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Basics of BRAF Speaker: R. Marais (United Kingdom) PLX 4032 and Follow-Up Molecules Speaker: K. Flaherty (USA) Combining TKI's in Melanoma: which Rationale, How and When Speaker: A. Ribas (USA) TKI's, BRAF Inhibitors and the Problem of New Toxicities such as Keratoacanthoma and Induction of Invasive SCC Speaker: C. Robert (France) Concluding Remarks Speaker: R. Marais (United Kingdom)
Oncology Nursing
Saturday 24 September 2011
Robotic Surgery - Opportunities and Issues for Nursing Speaker: S. Martin (United Kingdom) Health-Related Quality of Life as a Prognostic Factor in Patients With Oesophageal Cancer Speaker: P. Lagergren (Sweden) Discussion and Roundup
Special Session: Adolescent and Young Adult Cancer Patients: Are We Meeting Their Needs? ■■ 14:15 - 15:15 Chair: D. Kelly (United Kingdom)
Introduction Speaker: Y. Wengström (Sweden)
■■ 16:00 - 18:00 Chair: S. Kav (Turkey) Chair: U. Östlund (Sweden) Introduction Speaker: S. Kav (Turkey) Probiotics and Colon Cancer Prevention Speaker: J. Rafter (Sweden) Assessment and Management of Gastrointestinal Symptoms After Cancer Treatments Speaker: J. Andreyev (United Kingdom)
Patient-Centred Techologies the Future Is Here Speaker: N. Kearney (United Kingdom)
Continence Interventions - Bowel Problems Speaker: C. Taylor (United Kingdom)
Introduction of the ‘Health Buddy’ Into Patient Homes to Help Patients Who Are Receiving Palliative Chemotherapy Speaker: J. Korsten (The Netherlands)
The Experience of Living With a PEG Speaker: L. Martin (Sweden) Concluding Remarks Speaker: U. Östlund (Sweden)
Sunday 25 September 2011
Concluding Remarks Speaker: N. Kearney (United Kingdom)
Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 1): Basic Science of Lung Cancer
Special Session: Developments in Surgical Oncology
■■ 08:00 - 08:45 Speaker: H. Kristeleit (United Kingdom)
■■ 14:15 - 15:15 Chair: M. Wells (United Kingdom) Improving the Diagnostic Pathway for Men With Prostate Cancer Speaker: M. Emberton (United Kingdom)
Concluding Remarks Speaker: P. Dielenseger (France)
Special Session: Fertility Concerns
Chair: J. Denton (United Kingdom)
Male Infertility and Cancer Speaker: A. Pacey (United Kingdom) Same Sex Couples Fertility Issues Speaker: L. Moegelin (Sweden) Discussion and Roundup
Scientific Symposium: Probiotics, Calories and Cancer Care
Technologies and Challenges for Nurses and Health Care Speaker: D. Benton (Switzerland)
Using Technology in Palliative Care a Reality Speaker: B. Johnston (United Kingdom)
Neuropathies Speaker: E. Ryd Ausen (Sweden)
Frozen Hope: Fertility Preservation for Women With Cancer Speaker: J. Denton (United Kingdom)
Discussion and Roundup
Chair: N. Kearney (United Kingdom) Chair: Y. Wengström (Sweden)
Bone Disease - Osteoporosis Speaker: K. Leonard (Ireland)
Life Five Years Beyond Diagnosis Speaker: L. Wettergren (Sweden)
■■ 11:00 - 11:15
■■ 11:15 - 13:15
Cough Management in Lung Cancer Speaker: M. Bennett (United Kingdom)
■■ 13:15 - 14:15
Opening Session: Oncology Nursing Opening and Award Session
Scientific Symposium: Telethinking in Cancer Care
Cognitive Impairments Speaker: F. Munir (United Kingdom)
Why Are Adolescents Diagnosed Later With Cancer? Speaker: F. Gibson (United Kingdom)
Keeping Their World Together- NetworkFocused Nursing in Teenager and Young Adult Cancer Care Speaker: P.R. Olsen (Denmark)
EONS Distinguished Merit Award Speaker: To Be Announced
Introduction Speaker: A. Molassiotis (United Kingdom)
Advance Programme
Introduction Speaker: C. Robert (France)
Interactive Workshop: What Knowledge and Attitudes Do Paid Carers of People With Learning Disabilities Have About Cancer? ■■ 15:00 - 16:00 Coordinator: D.E. Wyatt (United Kingdom) Coordinator: P. Talbot (United Kingdom)
Society Session: European Oncology Nursing Society (EONS) - Couples (the Prostate Cancer Charity) ■■ 16:45 - 18:15 Theatre/Role Play on Prostate Cancer This Special Society Session will explore the project COUPLES. This was a unique artistic project between Professor Daniel Kelly (a member of the EONS Executive since 2007), the photographer Tim Wainwright, as well as a musician, a hospital arts co-ordinator and a theatre director. The project was funded by the 2008 Jeremy Gambrill Award and explores the impact of Prostate Cancer on various couples using photography, sound and extracts from interviews. Outcomes have included a specially designed website, a theatrical performance in London and a DVD. COUPLES explores the private impact of prostate cancer in a moving and challenging format. Daniel Kelly will present extracts from the project and the implications for using the Arts more widely as a vehicle to share the impact and experience of cancer.
Scientific Symposium: Symptom Management ■■ 09:00 - 11:00 Chair: A. Molassiotis (United Kingdom) Chair: P. Dielenseger (France)
Back To table of contents
23
Monday 26 September 2011
Scientific Symposium: Nursing Science ■■ 14:45 - 16:45
Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 2): Epidemiology of Lung Cancer
Chair: Y. Wengström (Sweden) Chair: D. Kelly (United Kingdom)
■■ 08:00 - 08:45
Introduction Speaker: Y. Wengström (Sweden)
Speaker: S.J. O'Connor (The Netherlands)
Scientific Symposium: Survivorship and Life Style Changes After Cancer (Diagnosis) ■■ 09:00 - 11:00 Chair: L. Sharp (Sweden) Chair: S. Faithfull (United Kingdom) Introduction Speaker: L. Sharp (Sweden) Breast Cancer and Return to Work Speaker: K. Alexanderson (Sweden) Addressing Consequences of Treatment: the Role of Rehabilitation Speaker: K. Robb (United Kingdom) The Role of Positive Psychology in Cancer Care Speaker: R. Bränström (Sweden) Cancer as a Teachable Moment Speaker: B. Byrne (United Kingdom) Concluding Remarks Speaker: S. Faithfull (United Kingdom)
Special Session: Developments and Management of Lymphoedema ■■ 13:15 - 14:15 Chair: M. Sneddon (United Kingdom) The Extent of the Problem Over Time Speaker: M. Sneddon (United Kingdom) Management Options Speaker: J. Simmons (United Kingdom) The Management of Lymphoedema in Advanced Cancer Speaker: A. Honnor (United Kingdom) Discussion and Roundup
Special Session: Optimal Care in Rare Cancers ■■ 13:15 - 14:15 Chair: L. Sharp (Sweden) Palliative Care Issues in Patients With Brain Tumours Speaker: C. Ostgathe (Germany) Kidney Cancers Speaker: E. Gustafsson (Sweden) Head and Neck Cancer Speaker: S. Kagan (USA) Discussion and Roundup
Patient-Centred Care - Building Capacity for Research and Clinical Care Speaker: I. Ekman (Sweden) Advanced Cancer Patients as Participants in Their Own Lives - a Qualitative Study of Coping From a Patient Perspective Speaker: T.G. Thomsen (Denmark) An Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation Therapy - a Clinical Controlled Randomised Trial Speaker: M. Jarden (Denmark) Towards Defining and Measuring the Fundamentals of Care Speaker: A. Kitson (Australia) Concluding Remarks Speaker: D. Kelly (United Kingdom)
Scientific Symposium: Transitions in Care for Cancer Patients ■■ 09:00 - 11:00 Chair: M. Browall (Sweden) Chair: B. Grube (Denmark) Introduction Speaker: B. Grube (Denmark) Ambulatory Care Speaker: K. White (Australia) Cultural Aspects in the Transition From Hospital to Community Care Speaker: E. Shadmi (Israel) Transition to Survivorship: Key Issues and Models of Care Speaker: M.S. McCabe (USA) Facilitating Transition to Palliative Care Speaker: M. Lloyd-Williams (United Kingdom) Concluding Remarks Speaker: M. Browall (Sweden)
Special Session: End of Life Care in Oncology ■■ 11:30 - 12:30
Debate: This House Believes That Alternative Therapies Have a Place in Cancer Care ■■ 17:00 - 18:00 Moderator: C. Tishelman (Sweden) Alternative Therapies Have a Place in Cancer Care Speaker in Favour: A. Molassiotis (United Kingdom) Alternative Therapies Do NOT Have a Place in Cancer Care Speaker Against: G. Eckerdal (Sweden) Alternative Therapies Have a Place in Cancer Care Seconder in Favour: T. Falkenberg (Sweden) Alternative Therapies Do NOT Have a Place in Cancer Care Seconder Against: C. Wylegalla (Germany) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Chair: P. Fernandez-Ortega (Spain) Recognising Dying and End-of-Life Prognostication in Elderly Cancer Patients Speaker: S.J. O'Connor (Belgium) Dying Well - Challenges in Acute Oncology Settings Speaker: P. Larkin (Ireland) Nurses Attitudes Towards Caring for Dying Patients in Acute Settings Speaker: M. Arantzamendi Solabarrieta (Spain) 12:00 Discussion and Roundup
Oncopolicy
Monday 26 September 2011 Oncopolicy Forum Session: Inequalities in Clinical Trials ■■ 09:00 - 11:00 Session: To Be Announced
Interactive Workshop: Dealing With Emotionally Challenging Patients or Families ■■ 17:00 - 18:00 Coordinator: L. Fallowfield (United Kingdom)
Tuesday 27 September 2011 Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 3): Chemotherapy in Lung Cancer
Oncopolicy Forum Session: Optimising Access to Cancer Drugs in Europe ■■ 13:15 - 14:15 Session: To Be Announced
Oncopolicy Forum Session: Inequalities in Research ■■ 14:45 - 16:45 Session: To Be Announced
■■ 08:00 - 08:45 Speaker: R. Lal (United Kingdom)
Oncopolicy Forum Session: European Partnership for Action Against Cancer ■■ 17:00 - 18:00 Session: To Be Announced
24
Back To table of contents
Tuesday 27 September 2011 Oncopolicy Forum Session: Inequalities in Access to Drugs and Quality of Care ■■ 09:45 - 11:30 Session: To Be Announced
Oncopolicy Forum Session: National Cancer Plans ■■ 11:30 - 12:30 Session: To Be Announced
Image Guidance for Temperature Sensitive Nanoparticle Drug Carriers Speaker: To Be Announced
Scanned Intensity-Modulated proton Therapy Speaker: A. Lomax (Switzerland)
Concluding Remarks Speaker: D. Verellen (Belgium)
Laser-Accelerated Proton Therapy Speaker: W. Enghardt (Germany)
Sunday 25 September 2011
Concluding Remarks Speaker: A. Lomax (Switzerland)
Scientific Symposium: Novel Oncoproteomic Technology
Paediatric Oncology
■■ 09:00 - 11:00 Chair: R. Aebersold (USA) Chair: G. Pestlin (USA)
Saturday 24 September 2011
Onco-Technology
Introduction Speaker: G. Pestlin (USA)
Long Term Follow Up in Childhood and Adolescent Cancer
Saturday 24 September 2011
Proteomics and Personalised Medicine Array Based Technologies Speaker: C. Jimenez (The Netherlands)
■■ 11:15 - 13:15
Scientific Symposium: Nanotechnologies for Targeted Drug Delivery ■■ 11:15 - 13:15 Chair: G. Storm (The Netherlands) Chair: R. Panicucci (USA) Introduction Speaker: G. Storm (The Netherlands) Nanoplatforms for Targeted Macromolecular Delivery Speaker: M.J. Alonso (Spain) Nanocarrier Pharmacokinetics and Pharmacodynamics: Watching Where Nanoparticles go Speaker: K. Kostarelis (United Kingdom) Pharmacokinetics and Pharmacodynamics of Drug Noanocarriers Speaker: To Be Announced Temperature Sensitive Drug Nanocarriers Speaker: H. Gruell (The Netherlands) Polymeric Nanoparticles and Drug Targeting Speaker: R. Panicucci (USA) Concluding Remarks Speaker: R. Panicucci (USA)
Scientific Symposium: New Image Guided Cancer Therapies ■■ 16:00 - 18:00 Chair: C. Moonen (France) Chair: D. Verellen (Belgium) Introduction C. Moonen (France) Application of MRI for Radiotherapy Dose Painting Speaker: U. Van der Heide (The Netherlands) Fluorescence Guided Cancer Therapy Speaker: P.K. Selbo (Norway) MRI Guided Focused Ultrasound in Brain Speaker: To Be Announced MRI Guided Focused Ultrasound Applications in the Body Speaker: F. Busse (Finland)
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Mass Spectrometry-Based Proteomics Speaker: To Be Announced Tissue Proteomics and the Molecular Phenotype Speaker: J. Celis (Denmark) Protein Kinase Activity and Therapy Response Speaker: K. Røe (Norway) Cancer Protein Biomarkers Speaker: R. Aebersold (USA)
Chair: K. Pritchard-Jones (United Kingdom) Chair: L.J. Hjorth (Sweden) Introduction Speaker: K. Pritchard-Jones (United Kingdom) Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Speaker: L.J. Hjorth (Sweden) The Epidemiology of Childhood Cancer Survivors Speaker: R. Haupt (Italy)
Concluding Remarks Speaker: R. Aebersold (USA)
Transition From Paediatric to Adult Care Models of Care Speaker: E. Frey (Austria)
Special Session: Assessment of Novel Oncotechnologies
Late Complications After Cancer in Childhood and Adolescence Speaker: G. Levitt (United Kingdom)
■■ 13:15 - 14:15 Chair: D.R. Olsen (Norway) Assessment of Novel Oncotechnologies Speaker: To Be Announced Randomised Clinical Trials in Assessment of Oncotechnologies Speaker: S.M. Bentzen (USA) Industry Perspective on Assessment of Oncotechnologies Speaker: To Be Announced Discussion and Roundup
Monday 26 September 2011 Scientific Symposium: Novel Radiation Technologies and Strategies ■■ 09:00 - 11:00 Chair: W. Enghardt (Germany) Chair: A. Lomax (Switzerland) Introduction Speaker: W. Enghardt (Germany) Adaptive Radiation Therapy Technology and Strategies Speaker: To Be Announced Integrated MRI-Guided Advanced Radiotherapy Speaker: J. Lagendijk (the Netherlands)
ICCCPO (the International Confederation of Childhood Cancer Parent Organisations) – the Survivors Perspectives Speaker: A. Kienesberger (Austria) Concluding Remarks Speaker: L.J. Hjorth (Sweden)
Scientific Symposium: Research Strategy of the Paediatric and Adolescents European Tumour Groups ■■ 16:00 - 18:00 Chair: M. Schrappe (Germany) Chair: A. Biondi (Italy) Introduction Speaker: M. Schrappe (Germany) Soft-Tissue Sarcomas Speaker: J. Chisholm (United Kingdom) High Risk Neuroblastoma Speaker: R. Ladenstein (Austria) Non Hodgkin Lymphomas Speaker: C. Patte (France) Relapsed Acute Lymphoblastic Leukemias Speaker: M. Schrappe (Germany) Very Rare Cancers in Children Speaker: G. Bisogno (Italy) Concluding Remarks Speaker: A. Biondi (Italy)
Back To table of contents
25
Sunday 25 September 2011
Introduction Speaker: J. Ricort (France)
Patient Advocacy / Ethics
Teaching Lecture: Medulloblastoma
Biology of IGF/IGFR Pathway in Ewing and Soft Tissue Sarcomas Speaker: H. Kovar (Austria)
Saturday 24 September 2011
■■ 08:00 - 08:45 Speaker: L. Padovani (France)
Special Session: The European Network for Cancer Research in Children and Adolescents (ENCCA) FP7 Project ■■ 13:15 - 14:15 Chair: R. Riccardi (Italy) European Network for Cancer Research in Children and Adolescents an FP7 Project (ENCCA) Speaker: R. Ladenstein (Austria) Integrating Activities of ENCCA Speaker: K. Pritchard-Jones (United Kingdom) Joint Research Activities of ENCCA Speaker: M. Schrappe (Germany) Spread of Excellence Activities of ENCCA Speaker: G. Vassal (France) Discussion and Roundup
Scientific Symposium: Brain Tumours in Children and Adolescents ■■ 14:45 - 16:45 Chair: D. Walker (United Kingdom) Chair: I. Slavc (Austria) Introduction Speaker: D. Walker (United Kingdom) Are Adult and Paediatric High Grade Gliomas the Same - Insight From Biology and Molecular Pathology Speaker: J. Grill (France) The EU Research Strategy for High Grade Glioma in Children and Adolescents – Can We Extrapolate From Adult Data? Speaker: D. Hargrave (United Kingdom) Molecular Characterisation of Medulloblastoma - the Route Towards Personalised Care Speaker: T. Pietsch (Germany) Functional Imaging in Adult and Paediatric Brain Tumours Speaker: A.C. Peet (United Kingdom) Concluding Remarks Speaker: I. Slavc (Austria)
Monday 26 September 2011 Teaching Lecture: Ewing Sarcoma Treatment ■■ 08:00 - 08:45 Speaker: H.F. Jürgens (Germany)
Scientific Symposium: The Role of IGFs/IGF-1R Pathway in Paediatric Malignancies ■■ 09:00 - 11:00
26
Chair: B.J. Morland (United Kingdom) Chair: J. Ricort (France) Back To table of contents
IGF1R Inhibitors in the Treatment of Ewing Sarcomas Speaker: L.J. Helman (USA) IGF1R Targeting in Non-Sarcoma Pediatric Malignancies Speaker: B. Geoerger (France)
Advocacy and Ethics Session: Getting Personal - Treatment in the Age of Targeted Therapies ■■ 11:15 - 13:15 Co-Chair: S. Kyriakides (Cyprus) Co-Chair: F. Cardoso (Portugal)
The IGF1 Growth Hormone Axis in Human Development Speaker: J. Ricort (France)
Personalised Medicine: Would it Work for Me? Speaker: R. Wilson (United Kingdom)
Concluding Remarks Speaker: B.J. Morland (United Kingdom)
Treating the Patient, Not Just The Disease Speaker: A. Novik (Russia)
Debate: This House Believes That Proton Therapy in Paediatric Oncology Improves Clinical Outcome ■■ 13:15 - 14:15 Moderator: B.L. Pizer (United Kingdom) Proton Therapy in Paediatric Oncology Improves Clinical Outcome Speaker in Favour: B. Timmermann (Switzerland) Proton Therapy in Paediatric Oncology Does NOT Improve Clinical Outcome Speaker Against: J.M. Michalski (USA) Proton Therapy in Paediatric Oncology Improves Clinical Outcome Seconder in Favour: J.L. Habrand (France) Proton Therapy in Paediatric Oncology Does NOT Improve Clinical Outcome Seconder Against: E. Halperin (USA) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Scientific Symposium: Drug Development in Paediatric Oncology ■■ 14:45 - 16:45 Chair: G. Vassal (France) Chair: B.J. Morland (United Kingdom) Introduction Speaker: B.J. Morland (United Kingdom) 4 Years Later - the Impact of the European Pediatric Medicine Regulation on Children and Adolescents in Europe Speaker: G. Vassal (France) PARP Inhibition in Pediatric Malignancies Speaker: A. Pearson (United Kingdom) Targeting ALK in Paediatric Malignancies Speaker: Y. Mosse (USA) Immunotherapy of Paediatric Malignancies Speaker: V. Minard-Colin (France) Apoptosis Research in Paediatric Malignancies - New Targets for Therapy Speaker: S. Fulda (Germany) Concluding Remarks Speaker: G. Vassal (France)
Challenges on the Road to Drug Approval Speaker: F. Pignatti (United Kingdom) Targeted Therapies: At What Cost? Speaker To Be Announced Personalised Medicine - Can Industry Deliver? Speaker: G. Guidi (Italy)
Court Room Trial: Patient Information on Trial ■■ 14:15 - 15:15 Judge: J. Bowis (United Kingdom) Prosecutor: I. Banks (United Kingdom) Defendant: Patient Information Expert Witnesses: L. Fallowfield (United Kingdom) K. Konstanty (Poland) E. Bergsten-Nordstrom (Sweden) I. Passarini (Belgium) Jury/Audience to Vote Guilty or Not Guilty
Advocacy and Ethics Session: The Challenges of Rare Cancers ■■ 16:00 - 18:00 Co-Chair: K. Oliver (United Kingdom) Co-Chair: R. Schaefer (Germany) 2.7 Million Reasons Why We Need to Improve the Rare Cancer Journey Speaker: K. Oliver (United Kingdom) Rarity and Research- Challenges for the International Cancer Community Speaker: J.Y. Blay (France) Rare Cancer Advocacy Groups and the EMA Creating a Sustainable Partnership Speaker: K. Westermark (Sweden)
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
We Are Here To Help - How Patient Organisations Can Help You Navigate on the Journey Speaker: S. Craine (United Kingdom)
Sunday 25 September 2011 Advocacy and Ethics Session: Cancer at Any Age - Ethics and Challenges
Special Session: Not Just Research Subjects, but Research Allies - Patient Involvement in The Design, Conduct and Dissemination of Clinical Trials ■■ 17:15 - 18:15 Moderator: R. Sullivan (United Kingdom) Panel: A. Arber (United Kingdom), I. Klingmann (Belgium), A. Fehervary (Italy), D. Lacombe (Belgium), R. Wilson (United Kingdom) G. Cruickshank (United Kingdom)
■■ 09:00 - 11:00 Co-Chair: T. Hudson (Ireland) Co-Chair: L. Jost (Switzerland) Ethical Learnings from Paediatric Cancer Research Speaker: D. Walker (United Kingdom) Ethical Dilemmas in the Management of Teenage Cancer Patients Speaker: F. Gibson (United Kingdom) To Enrol or Not to Enrol - Ethical Considerations for Clinical Trial Participation Speaker: N. Stingelin (Switzerland) Too Old to Be Treated? Speaker: M. Aapro (Switzerland) Palliative Care: More Than Just End of Life Treatment Speaker: N. Cherny (Israel)
Radiobiology/Radiation Physics/Radiotherapy
Sunday 25 September 2011 Teaching Lecture: New Technology in Radiotherapy ■■ 08:00 - 08:45 Speaker: J. Kazmierska (Poland)
Scientific Symposium: Impact of Tumour Hypoxia on Heterogeneity in Radiation Response ■■ 09:00 - 11:00 Chair: J. Overgaard (Denmark) Chair: J. Bussink (The Netherlands) Introduction Speaker: J. Bussink (The Netherlands)
Saturday 24 September 2011
Cellular Response to Hypoxia Speaker: L. DuBois (The Netherlands)
Teaching Lecture: Radiotherapy of Prostate Cancer
Hypoxia Imaging and Outcome After Radiotherapy: Pre-Clinical Results Speaker: J. Overgaard (Denmark)
■■ 08:00 - 08:45 Speaker: V. Khoo (United Kingdom)
Scientific Symposium: Improving the Therapeutic Ratio of Radiotherapy: New Concepts to Protect Normal Tissues ■■ 11:15 - 13:15 Chair: M. Vozenin-Brotons (France) Chair: D. Zips (Germany)
Hypoxia Imaging and Outcome After Radiotherapy: Clinical Results Speaker: P. Dirix (Belgium) Translational Aspects of Hypoxia Modification Speaker: P. Hoskin (United Kingdom) Concluding Remarks Speaker: J. Overgaard (Denmark)
Advocacy and Ethics Session: Cancer and the Internet
Introduction Speaker: M. Vozenin-Brotons (France)
Special Session: New Insights in Molecular Targeting in Radiotherapy
■■ 13:15 - 14:15
Molecular Targeting to Protect Normal Tissues Speaker: W. Doerr (Germany)
■■ 13:15 - 14:15
Chair: J. Geissler (Germany) Eurocancercoms: Cancer Superportal Speaker: R. Sullivan (United Kingdom) Serving Patient Communities Through Social Media Speaker: D. Costello (France) Running Sustainable Online Communities Speaker: G. Frydman (United States of America)
Advocacy and Ethics Session: Cancer Research - Ethics and Challenges ■■ 14:45 - 16:45 Co-Chair: I. Kössler (Sweden) Co-Chair: N. Wilking (Sweden) Clinical trials - Are Patients 'Lost in Translation'? Speaker: P. Garcia-Prieto (Belgium) Ethics in Cancer Biobanking Speaker: K. Zatloukal (Austria) Patient Advocates and Ethical Review Boards Speaker: P. Knupfer (Germany) Should ALL Trial Results - Good and Bad be Published and Made Publicly Available? Speaker: U. Ringborg (Sweden) Conventional Medicine and CAM a Happy Partnership? Speaker: H. Jernström (Sweden)
Stem Cells: Role for Radiation Response and Therapeutic Approaches Speaker: R. Coppes (The Netherlands) Possible Intervention Strategies to Reduce Radiation-Induced Heart Disease Speaker: S. Hoving (The Netherlands) Modern Radiotherapy Techniques to Spare Normal Tissues Speaker: C. Nutting (United Kingdom) Concluding Remarks Speaker: D. Zips (Germany)
Special Session: Immune System and Tumour Response to Radiotherapy
Chair: J. Alsner (Denmark) EGFR-Inhibition: Pre-Clinical and Clinical Update Speaker: M. Krause (Germany) New Molecular Targets in the Tumour Speaker: E. Deutsch (France) Molecular Pathways in Radiation Fibrosis Speaker: M. Vozenin-Brotons (France) Discussion and Roundup
Debate: This House Believes That Adaptive Radiotherapy Reduces Side Effects and Allows Treatment Intensification ■■ 15:00 - 16:00
■■ 14:15 - 15:15
Moderator: J. Bourhis (France)
Chair: G. Kroemer (France)
Adaptive Radiotherapy Reduces Side Effects and Allows Treatment Intensification Speaker in Favour: S.M. Bentzen (USA)
14:15 Introduction Speaker: G. Kroemer (France) Role of T-Lymphocytes for Tumour Response to Radiotherapy Speaker: S. Formenti (USA) CD11b Cells Provide Resistance to Radiotherapy Speaker: M.J. Brown (USA) Discussion and Roundup
Advance Programme
The RARECARE Initiative Speaker: P.G. Casali (Italy)
Adaptive Radiotherapy Does NOT Reduce Side Effects and Allows Treatment Intensification Speaker Against: V. Gregoire (Belgium) Adaptive Radiotherapy Reduces Side Effects and Allows Treatment Intensification Seconder in Favour: D. De Ruysscher (The Netherlands)
Back To table of contents
27
Adaptive Radiotherapy Does NOT Reduce Side Effects and Allows Treatment Intensification Seconder Against: V. Budach (Germany) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Special Session: Stereotactic Radiotherapy for Liver Metastases
Sunday 25 September 2011
■■ 11:30 - 12:30
Scientific Symposium: The Application of Pharmacometrics in Oncology
Chair: E. Lartigau (France) Radiobiological Aspects of RadiationInduced-Liver-Disease Speaker: H. Christiansen (Germany)
Chair: P. Hartvig (Denmark) Chair: A. Astier (France)
Monday 26 September 2011
Clinical Results Speaker: L.A. Dawson (Canada)
Introduction Speaker: P. Hartvig (Denmark)
Teaching Lecture: Radiation Therapy and Radioisotopes for Bone Metastases: What Is Their Real Benefit?
Technical Requirements and Quality Assurance Speaker: L.P. Muren (Denmark)
Application of Population PK-PD Methods in Oncology Speaker: E. Chatelut (France)
■■ 08:00 - 08:45
Discussion and Roundup
Considerations in PK-PD of Antibodies Speaker: C. Kloft (Germany)
Speaker: U. Nestle (Germany)
Special Session: Advanced Technology for Radiotherapy ■■ 13:15 - 14:15 Chair: E.B. Hug (Switzerland) Clinical Experience With Carbon Ion Radiotherapy Speaker: J. Debus (Germany) Protons for Radiotherapy of Lung Cancer Speaker: M. Stuschke (Germany) Advanced Photon Therapy Speaker: D. Verellen (Belgium) Discussion and Roundup
Tuesday 27 September 2011 Teaching Lecture: Combining Molecular Targeted Agents and Radiotherapy ■■ 08:00 - 08:45 Speaker: T. Brunner (United Kingdom)
Regulatory / Trial Methodology / Pharmacy
Saturday 24 September 2011 Special Session: Issues in Economic Evaluation of New Cancer Therapies ■■ 14:15 - 15:15 Chair: D. Parkinson (USA) Cancer Drug Costs - Forecast for Europe Will the Cost Explode? Speaker: N. Wilking (Sweden) Methodological Issues in Economic Evaluation of New Cancer Therapies Speaker: To be Announced Performance-Based Agreement Theory to Practice- the Current Use in Oncology and Future Trend Speaker: B. Jönsson (Sweden) Discussion and Roundup
Scientific Symposium: Partial Breast Irradiation ■■ 09:00 - 11:00 Chair: J.R. Yarnold (United Kingdom) Chair: P. Poortmans (The Netherlands) Introduction Speaker: J.R. Yarnold (United Kingdom) Clinical Radiobiology of Partial Breast Irradiation Speaker: C. Petersen (Germany) Partial Breast Irradiation With External Beam Radiotherapy Speaker: R. Orecchia (Italy) Brachytherapy for Partial Breast Irradiation Speaker: E. Van Limbergen (Belgium) Summary: Concept, Rationale, Evidence and Future Directions Speaker: J.R. Yarnold (United Kingdom) Concluding Remarks Speaker: P. Poortmans (The Netherlands)
Scientific Symposium: Clinical Trial Methodology ■■ 16:00 - 18:00 Chair: S.B. Kaye (United Kingdom) Chair: C. Dittrich (Austria) Introduction Speaker: S.B. Kaye (United Kingdom) How to Optimise the Preclinical to Phase I Transition? Speaker: C. Twelves (United Kingdom) Novel Designs and Alternate Endpoints for New Drug Studies Speaker: C. Dittrich (Austria) How to Optimise Strategies for Clinical Development of Combinations Based on Targeted Agents ? Speaker: A. Awada (Belgium) Are Big Phase III Realistic in The Era of Personalised Medicine? Non-traditional Approaches for Registration Speaker: M. Rothenberg (USA) Concluding Remarks Speaker: C. Dittrich (Austria)
28
■■ 09:00 - 11:00
Back To table of contents
Pharmacometrics to Improve Teatment of Cancer in Children Speaker: A. Huitema (The Netherlands) Optimising Phase I Trials With Modelling and Simulation using Pharmacometrics Speaker: I. Trocóniz (Spain) Concluding Remarks Speaker: A. Astier (France)
Special Session: Cross-Over in Trials ■■ 13:15 - 14:15 Chair: I.F. Tannock (Canada) Early Approval Versus Late Approval Speaker: F. Pignatti (United Kingdom) What Are the Current Thoughts on CrossOver Designs? Speaker: D. Sargent (USA) Cross-Over - the Clinician's Perspective Speaker: I.F. Tannock (Canada) Discussion and Roundup
Debate: This House Believes That Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected ■■ 15:00 - 16:00 Moderator: D. Lacombe (Belgium) Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected Speaker in Favour: P.E. Goss (USA) Prospective Randomised Trials Should NOT Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected Speaker Against: J. Bogaerts (Belgium) Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected Seconder in Favour: M. Castiglione-Gertsch (Switzerland) Prospective Randomised Trials Should NOT Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected Seconder Against: C. Dittrich (Austria) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Sarcoma: Soft Tissue and Bone
Preoperative Chemotherapy is Standard of Care in Soft Tissue Sarcoma Seconder Against: A. Le Cesne (France)
Neoadjuvant Treatment – Better than Surgery Alone? Speaker: T. Lehnert (Germany)
Monday 26 September 2011
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Will Centralisation Improve Outcome? Speaker: R.C. Mason (United Kingdom)
Special Session: Management of Retroperitoneal Sarcoma ■■ 13:15 - 14:15 Chair: S. Bonvalot (France) Differential Diagnosis of Retroperitoneal Sarcoma Speaker: P.C.W. Hogendoorn (The Netherlands) Surgical Management of Primary Retroperitoneal Sarcomas: Improving Outcomes Speaker: D. Strauss (United Kingdom) The Role of Radiotherapy in Retroperitoneal Sarcoma Speaker: F. Saran (United Kingdom) Discussion and Roundup
Scientific Symposium: New Avenues in Soft Tissue Sarcoma ■■ 14:45 - 16:45 Chair: P. Schöffski (Belgium) Chair: K. Sundby Hall (Norway) Introduction Speaker: P. Schöffski (Belgium) Inappropriate Initial Approaches to Soft Tissue Sarcoma (Clinical, Biopsy, Surgery, Imaging) Speaker: A. Hayes (United Kingdom)
Tuesday 27 September 2011 Teaching Lecture: Soft Tissue Sarcomas: Are All Soft Tissue Sarcomas Treated With the Same Drugs?
Discussion and Roundup
Monday 26 September 2011 Teaching Lecture: Skin-Sparing Mastectomy
■■ 08:00 - 08:45 Speaker: A.D. Baildam (United Kingdom)
■■ 08:00 - 08:45 Speaker: J.Y. Blay (France)
Scientific Symposium: Contributors to Better Survival in Colorectal Cancer
Special Session: Desmoid Fibromatosis Tumours Representing an Unmet Medical Need
■■ 14:45 - 16:45
■■ 11:30 - 12:30 Chair: P. Hohenberger (Germany) How Much Surgery and When? Speaker: A. Gronchi (Italy) Radiotherapy as Adjuvant Treatment to Surgery or as Definitive Treatment? Speaker: V. Budach (Germany) Systemic Treatments for Desmoids Fibromatosis Speaker: I. Judson (United Kingdom) Discussion and Roundup
Surgical Oncology
Chair: C.J.H. van de Velde (The Netherlands) Chair: A.F. Sobrero (Italy) Introduction Speaker: A.F. Sobrero (Italy) The Contribution of Evidence Based Guidelines and Compliance to Colon Cancer Survival Speaker: G. Poston (United Kingdom) Better Staging Leads to Better Survival in Colon Cancer; the Sentinel Node Reappraised Speaker: M. Zuber (Switzerland) Neoadjuvant Treatment in Colon Cancer Speaker: A.F. Sobrero (Italy) The Role of Radiotherapy for Better Survival in Rectal Cancer Speaker: C. Rödel (Germany) Making Non-Resectable Colorectal Cancer Resectable Speaker: W. Hohenberger (Germany)
Soft Tissue Sarcoma as a Role Model for Targeted Treatment and Drug Development Speaker: J.Y. Blay (France)
Saturday 24 September 2011
Innovative Radiotherapy Approaches in Soft Tissue Sarcoma Speaker: P. Scalliet (Belgium)
Special Session: Peritoneal Surface Oncology - the Evidence for Locoregional Treatment
Concluding Remarks Speaker: C.J.H. van de Velde (The Netherlands)
Who Needs a (New) Histopathological and/or Molecular Classification? Speaker: A.P. Dei Tos (Italy)
■■ 14:15 - 15:15
Tuesday 27 September 2011
Concluding Remarks Speaker: K. Sundby Hall (Norway)
Debate: This House Believes That Preoperative Chemotherapy Is Not Yet Standard of Care in Soft Tissue Sarcoma ■■ 17:00 - 18:00 Moderator: F. Van Coevorden (The Netherlands) Preoperative Chemotherapy is NOT Yet Standard of Care in Soft Tissue Sarcoma Speaker in Favour: I. Judson (United Kingdom) Preoperative Chemotherapy is Standard of Care in Soft Tissue Sarcoma Speaker Against: A. Gronchi (Italy) Preoperative Chemotherapy is NOT Yet Standard of Care in Soft Tissue Sarcoma Seconder in Favour: J. Verweij (The Netherlands)
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Chair: S. Gonzalez-Moreno (Spain) Peritoneal Carcinomatosis of Colorectal Origin Speaker: F. Quenet (France) Peritoneal Mesothelioma Speaker: M. Deraco (Italy) Pseudomyxoma Peritonei Speaker: S. Gonzalez-Moreno (Spain) Discussion and Roundup
Sunday 25 September 2011
Teaching Lecture: Overview on the Role of Laparoscopic Surgery in Cancer Management ■■ 08:00 - 08:45 Speaker: P. Willemsen (Belgium)
Special Session: Surgical Treatment in Breast Cancer Patients With Distant Metastases ■■ 11:30 - 12:30 Chair: M. Leidenius (Finland)
Special Session: Esophageal Cancer Ways to Improve Outcome
Surgery of the Primary Tumour Speaker: G. Vlastos (Switzerland)
■■ 13:15 - 14:15
Surgery of Liver and Pulmonary Metastases Speaker: R. Adam (France)
Chair: T. Lehnert (Germany) How Radical Should Surgery Be? Speaker: C. Mariette (France)
Discussion and Roundup
Back To table of contents
29
Symptom Science
Tuesday 27 September 2011
Sunday 25 September 2011
Scientific Symposium: Relieving Symptoms of Hormonal Therapies in Patients With Breast Cancer
Scientific Symposium: Improved Pain Control Through a Collaborative Approach Between Oncology, Pain and Palliative Care Specialists ■■ 14:45 - 16:45 Chair: S. Kaasa (Norway) Chair: D. Büche (Switzerland) Introduction Speaker: D. Büche (Switzerland) How to Improve Cancer Pain Control Through European Guidelines for Opioid Treatment and Cancer Pain Diagnosis Speaker: S. Kaasa (Norway) What Is the Place of and Effect of Chemotherapy Including Modern Targeted Therapies to Prevent and to Treat Cancer Pain Speaker: N.I. Cherny (Israel) What Is the Place for an Effect of Surgery to Prevent and/or to Treat Cancer Pain Speaker: B. Axelsson (Sweden) What Is the Place and Effect of Radiotherapy and What Is the Optimal Schedule for Cancer Pain Speaker: P. Hoskin (United Kingdom) A Future Research Agenda to Improve Pain Control Through Collaborative Efforts Speaker: D. Büche (Switzerland) Concluding Remarks Speaker: S. Kaasa (Norway)
Monday 26 September 2011 Teaching Lecture: Emergency and Palliative Care ■■ 08:00 - 08:45 Speaker: D. Schrijvers (Belgium)
Scientific Symposium: Treatment of Dyspnea - What Does the Evidence Support? ■■ 14:45 - 16:45 Chair: S. Börjeson (Sweden) Chair: N.I. Cherny (Israel) Introduction Speaker: S. Börjeson (Sweden) Inhaled Furosemide - Yes or No? Speaker: S. Booth (United Kingdom) Opioids Speaker: I. Ben Aharon (Israel) Benzodiazepines Speaker: S.T. Simon (United Kingdom) Pleural Effusion Management Speaker: P. Girard (France) Concluding Remarks Speaker: N.I. Cherny (Israel)
30
Back To table of contents
■■ 09:00 - 11:00 Chair: M. Aapro (Switzerland) Chair: Y. Wengström (Sweden) Introduction Speaker: M. Aapro (Switzerland) Endocrine Symptom Assessment in Women With Breast Cancer Speaker: K. Ribi Brega (Switzerland) Evidence-Based Management of Symptoms Related to Endocrine Treatment Speaker: Y. Wengström (Sweden) Identification and Management of Treatment-Related Symptoms for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy Speaker: L. Fallowfield (United Kingdom) Non-Compliance in the Adjuvant Endocrine Treatment of Women With Breast Cancer Speaker: P. Peyman Hadji (Germany) Concluding Remarks Speaker: Y. Wengström (Sweden)
Translational Research
Saturday 24 September 2011 Special Session: Immunotherapy the Future ■■ 14:15 - 15:15 Chair: To Be Announced Immunochemotherapy Speaker: L. Zitvogel (France) DNA Vaccination Speaker: J.B.A.G. Haanen (The Netherlands) Combined Radiotherapy and Immunoradiotherapy Speaker: J. Hodge (USA) Discussion and Roundup
Scientific Symposium: Anti-Angiogenic Strategies for Cancer ■■ 16:00 - 18:00 Chair: A.L. Harris (United Kingdom) Chair: E. Van Cutsem (Belgium) Introduction Speaker: A.L. Harris (United Kingdom) Vasculogenesis or Angiogenesis in Determining Tumour Regrowth After Cancer Therapy Speaker: M.J. Brown (USA) Hypoxia-Driven Angiogenesis Speaker: P. Carmeliet (Belgium)
Anti-angiogenesis: Local Anti-Tumour Effect but Accelerated Metastases? Speaker: R.S. Kerbel (Canada) Biomarkers & Angiogenesis Speaker: J.V. Heymach (USA) Concluding Remarks Speaker: E. Van Cutsem (Belgium)
Monday 26 September 2011 Scientific Symposium: Tailoring Personalised Medicine for The Future ■■ 09:00 - 11:00 Chair: U. Ringborg (Sweden) Chair: A.H. Ree (Norway) Introduction Speaker: U. Ringborg (Sweden) Biomarkers in Early Phase Therapy Trials Speaker: A. Adjei (USA) Personalised Therapy in Breast Cancer Speaker: S. Linn (The Netherlands) Personalised Therapy in Lung Cancer Speaker: R. Rosell (Spain) Biomarkers: Differences Between Medical Oncology Versus Radiotherapy Speaker: M. Krause (Germany) Concluding Remarks Speaker: A.H. Ree (Norway)
Special Session: Hitting the Right Pathway: New Drugs for New Targets ■■ 13:15 - 14:15 Chair: F. Cappuzzo (Italy) MET Inhibitors Speaker: P. Jänne (USA) RAF Inhibitors Speaker: F. Di Nicolantonio (Italy) ALK Inhibitors Beyond Lung Speaker: R. Doebele (USA) Discussion and Roundup
Tuesday 27 September 2011 Teaching Lecture: Translational Genomics in Breast Cancer ■■ 08:00 - 08:45 Speaker: C. Caldas (United Kingdom)
Scientific Symposium: PARP Inhibiting Strategies: From Molecular Mechanisms to Rational Clinical Application ■■ 09:00 - 11:00 Chair: M. Verheij (The Netherlands) Chair: T. Helleday (United Kingdom)
Introduction Speaker: M. Verheij (The Netherlands)
Tuesday 27 September 2011
Cellular Responses to DNA Damage: Molecular Insights and New Strategies for Cancer Therapy Speaker: S. Bhide (United Kingdom)
Scientific Symposium: Managing the Side Effects
Preclinical Evaluation of PARP Inhibitors in Mouse Models of Human Breast Cancer Speaker: J. Jonkers (The Netherlands) Combining PARP Inhibitors With DNA Damaging Agents: Clinical Studies Speaker: D. Fennell (United Kingdom) Radiosensitisation By PARP Inhibition Speaker: A. Chalmers (United Kingdom) Concluding Remarks Speaker: T. Helleday (United Kingdom)
Young Oncologists
Sunday 25 September 2011 Special Session: Tips and Tricks to Be the Best ■■ 13:15 - 14:15 Chair: I.R.H.M. Konings (The Netherlands) Surgeon Speaker: A. Maciejewski (Poland) Clinical Oncologist Speaker: S. Sleijfer (The Netherlands) Radiation Oncologist Speaker: D. Zips (Germany) Discussion and Roundup
Monday 26 September 2011 Special Session: How to Write and Review a Good Article? ■■ 17:00 - 18:00 Chair: M. Hutka (Poland) The Point of View of the Editor Speaker: M. Baumann (Germany)
Advance Programme
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
■■ 09:00 - 11:00 Chair: D. Gabrys (Poland) Chair: E. Martinelli (Italy) Introduction Speaker: D. Gabrys (Poland) Early and Late Side Effects Related to Surgery Speaker: C. Verhoef (The Netherlands) Combination of Radiotherapy and Targeted Agents: What Should We Expect? Speaker: M. Brada (United Kingdom) Is It Time to Review the Common Toxicity Criteria in the Era of New Targeted Drugs? Speaker: J. Jassem (Poland) How to Follow Up the Acute and the Late Toxicity With New Emerging Therapies? Speaker: Z. Liao (USA) Concluding Remarks Speaker: E. Martinelli (Italy)
Debate: This House Believes That Overall Survival Is the Only Endpoint for Drug Approval ■■ 11:30 - 12:30 Moderator: T. Le Chevalier (France) Overall Survival Is the Only Endpoint for Drug Approval Speaker in Favour: S. Di Cosimo (Spain) Overall Survival Is NOT the Only Endpoint for Drug Approval Speaker Against: M. di Maio (Italy) Overall Survival Is the Only Endpoint for Drug Approval Seconder in Favour: A. Kramar (France) Overall Survival Is NOT the Only Endpoint for Drug Approval Seconder Against: M. Buyse (Belgium) Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
The Point of View of a Statistician Speaker: L. Collette (Belgium) How to Get Good Evidence Based Information Speaker: T. Troiani (Italy) Discussion and Roundup
Back To table of contents
31
Leading provider of Oncology content The European Journal of Cancer (including EJC Supplements), is an international comprehensive Oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. The European Journal of Cancer (including EJC Supplements) is the official Journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).
For more information (including online submissions) visit: www.ejcancer.info
OncologySTAT is where Hem/Onc professionals like you go when search engines don’t meet your needs: too many results, most for patients (not professionals like you), and nothing organized or validated. Edited by leaders in Oncology, OncologySTAT has more scientific and practice-changing content than any other oncology website—breaking news, journal scans, abstracts, expert opinion, chemo regimens, drug information, CME and more. OncologySTAT is also the gateway to tens of thousands of pages of full text, peer-reviewed original research and reviews from over 100 leading cancer journals. Best of all, everything is sorted by cancer type, the way you need it. Come to OncologySTAT for the information and resources that can change how you fight cancer as a practitioner or a researcher. All the answers you need, all in one place.
For more information and to register for FREE visit: www.oncologystat.com
The Lancet Oncology is a lively monthly journal containing original research, reviews, opinion, and news covering international issues relevant to clinical cancer specialists worldwide. The journal has quickly established itself as one of the premier journals worldwide for original research, especially reports from clinical trials. Uniquely, all original research is peer-reviewed via a fast-track service, and successful papers are published within 8 weeks of submission.
For more information visit: www.thelancet.com/oncology
Cancer Cell publishes reports of novel results in any area of cancer research, from molecular and cellular biology to clinical oncology. The work should be not only of exceptional significance within its field but also of interest to researchers outside the immediate area. In addition, Cancer Cell findings in cancer research, diagnosis and treatment. The goal of Cancer Cell is to promote the exchange of ideas and concepts across the entire cancer community, cultivating new areas of basic research and clinical investigation. Cancer Cell will consider papers for publication in any aspect of cancer biology and clinical research, including (but not limited to): Genetics, epigenetics, genomic instability • Cell signaling and communication • Cell cycle, DNA repair • Diagnostics (molecular profiling, pharmacogenomics) • Telomerase and transformation • Apoptosis • Angiogenesis, metastasis • Animal models • Cancer therapy (rational drug design, small molecule therapeutics) • Epidemiology and prevention.
For more information visit: www.cell.com/cancer-cell
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Abstracts can only be submitted online on the ECCO website at: www.ecco-org.eu. Abstracts submitted by post, fax or E-mail will NOT be accepted. Abstract submission deadline is 18 April 2011, 09.00 p.m. (21:00 hrs) Central European Time.
The 2011 European Multidisciplinary Cancer Congress abstract submission programme is available on the ECCO website, www.ecco-org.eu.
• Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the
CALL FOR ABSTRACTS
Call for Abstracts
2011 European Multidisciplinary Cancer Congress • For important large studies, presented (in part) at previous meetings, authors are encouraged to provide updated data. Violation of this policy may result in a rejection of the submitted abstract. • Certifies that the information in the abstract is for exclusive presentation in the 2011 European Multidisciplinary Cancer Congress scientific programme and will not be presented as such during the conference at any industry-related satellite symposia.
It is strongly advised that presenting authors
• States that for all studies involving human or animal
should submit their abstract before the day of
subjects, permission has been obtained from the
the deadline, otherwise authors may experience
relevant regulatory authority and properly informed
technical delay due to server overload.
consent given where appropriate • Abstracts that include clinical trial data include the
The 2011 European Multidisciplinary Cancer Congress Scientific Committee strongly encourages the submission of abstracts on Phase I, Phase II and large Phase III trials coming to an end or having new data available mid 2011. Please refer to “Late-Breaking Abstracts Policy & Regulations” on page 35.
following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s) • Identifies any financial interest in products or processes described in the abstract. The presenting author is requested to tick the “Conflict of interest”
Abstracts on case studies will be rejected.
box when submitting the abstract and to provide
1. Abstract Policies and Regulations
abstract submission programme. This includes stock
With the submission of an abstract to 2011 European Multidisciplinary Cancer Congress, the first (presenting) author:
ownership, membership on an advisory board or
• Certifies to be an investigator with a substantial
disclosure of interests and relationships through the
board of directors, corporate-sponsored research, or other substantive relationships. • Releases the copyright to ECCO and gives permission
involvement in the clinical study presented in the
for the abstract, when selected for presentation, to
abstract.
be published in the 2011 European Multidisciplinary
• Accepts responsibility for the accuracy of the
Cancer Congress Abstract book with the European
submitted abstract (please proofread the abstract
Journal of Cancer Supplement (in printed and
carefully prior to submission!)
electronic format), as well as on the ECCO website.
• Accepts to be the contact person for all correspondence about the abstract and inform
2. Abstract Preparation and Submission
co-authors about its status.
a. Abstract Format
• Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
• The title of the abstract should be brief, and in Title Case, objectively describing the study. Do not use non-standard abbreviations and commercial names (generic names only).
Back To table of contents
33
• No more than 10 authors can be listed with
• If you need to edit your abstract at a later stage
institutional affiliations, cities and countries only.
please click 'SAVE AND CLOSE'. This button allows
Mailing addresses and academic degrees should not
you to update your abstract before final submission.
be mentioned in the author’s list. For cooperative
Please note: after clicking 'SAVE AND CLOSE', your
study groups, you may give the name of the group
abstract is NOT submitted. You need to return
instead of individual institutional affiliations or
to the abstract submission page, finalise your
include the name of the group in the title of the
abstract and click 'FINAL SUBMISSION'.
abstract. • Abstracts should be structured in such a way as to include the following 4 sections:
• Within 48 hours of submission, the presenting author will receive an e-mail to confirm that ECCO has received the abstract. This confirmation of abstract
Background : an introductory sentence indicating
does not mean your abstract has been selected for
the purpose of the study
presentation.
Material and methods: a brief description of
• In case the confirmation from the 2011 European
pertinent experimental procedures
Multidisciplinary Cancer Congress Secretariat is
Results : a summary of the results of the research
not received, please contact the secretariat
Conclusions : a statement of the main conclusions
(pat.vanhove@ecco-org.eu) within one week after
• The on-line abstract submission procedure will not accept abstracts that exceed 2.500 characters (body of the abstract, including spaces and table) • Only one data table is permitted in the body of the abstract. Illustration and figures are not allowed and will be deleted if submitted. • Abbreviations may be used if standard or if spelled
the submission of the abstract. • Submitting an abstract for presentation in the 2011 European Multidisciplinary Cancer Congress does not constitute registration for the conference. Abstract presenters must register to attend the 2011 European Multidisciplinary Cancer Congress by following the instructions for registration on the website
out and defined at the first use (put in parentheses immediately after the first mention of a term or
Presentation Preference
phrase). Compounds should be mentioned with
Oral, poster or no preference: the final decision
the generic name, in lower cases. Commercial
on the presentation format will be made by the
names are admitted in the text, with an ®, and if in
Scientific Committee.
brackets following the generic name, i.e. “generic (Commercial ®)”. • The abstract must be submitted in good English.
3. Topic Categories Please select ONE abstract topic and ONE abstract
The Scientific Committee reserve the right to reject
sub topic which refers to the main subject of the
those abstracts which are presented in poor English,
abstract.
or may request an immediate revision by the presenter.
b. Abstract Submission Procedure Abstracts must be submitted on-line, through the ECCO website at: www.ecco-org.eu. Essential information • When finished with the online submission, click the ‘FINAL SUBMISSION’ button for the final submission of your abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
34
Back To table of contents
Keywords: Authors have to provide 3 keywords
(different from category). The Scientific Committee has the authority to re-categorise and re-key the abstract. For questions regarding the on-line submission process please email Pat Vanhove at: pat.vanhove@ecco-org.eu. For the list of abstract topic categories please see page 37.
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Abstracts submitted for presentation in the 2011 European Multidisciplinary Cancer Congress will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted.
5. ‘Late-Breaking Abstracts’ Policy and Regulations Late-Breaking Abstract submission deadline is
CALL FOR ABSTRACTS
4. Abstract Selection Process
10 August 2011, 09.00 p.m. (21:00 hrs) Central European Time.
Definition The following presentation formats are applicable at the 2011 European Multidisciplinary Cancer Congress: Oral presentation: the abstract is selected for oral
presentation at any of the proffered papers sessions. Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective. Poster session: abstracts that have been selected
for presentation in poster format will be displayed on poster boards. The posters are grouped by topic and are displayed for four hours. A specific time is devoted to poster viewing. Poster discussion session: experts in the field
are chosen to provide a themed overview and discussions of the findings from selected abstracts. First authors of abstracts that have been selected for poster discussion session will be invited to submit the poster electronically prior to the congress (details will follow in due time). Abstracts will be made available two weeks before the Congress. Presenting authors will be contacted to give their consent. Withdrawal of abstracts: Abstracts submitted for
the 2011 European Multidisciplinary Cancer Congress can be withdrawn until Wednesday 4 May 2011 . After this date, abstracts selected for oral or poster presentation should be presented. If the presenting author of a selected abstract cannot attend, (s) he should assign a replacement and inform ECCO of the replacement as soon as possible. The presenting author will receive a letter with the result of the review and the Scientific Committee’s decision on the abstract by end of June/beginning of July.
• Late-breaking abstracts should highlight novel and practice changing studies. The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline. It will focus on capturing abstracts with groundbreaking and unique data that would not otherwise have been presented at the Congress. • Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications; in each case the results should not have been fully available by the general abstract submission deadline. • The data in the abstract must not be published (manuscript or abstract) prior to the Congress.
Policy • Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the abstract submission deadline of 18 April 2011, will be considered for presentation at the 2011 European Multidisciplinary Cancer Congress • Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please ask for special consideration by email. • Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
Back To table of contents
35
• Late-breaking abstracts will be considered for oral presentation either in proffered papers sessions or in one of the Presidential sessions. If a latebreaking abstract does not meet the criteria for oral presentation in one of these two sessions, the abstract will be rejected • Late-breaking abstracts will undergo formal peerreview evaluation by the Scientific Committee
Submission A call for late-breaking abstracts will be made in June. Online submission will be open from 27 July 2011 until 10 August 2011.
The first (presenting) author must: • Submit a late breaking abstract by the submission deadline of 10 August 2011 • Complete the section on the reasons why this abstract should be considered as late-breaking (In order for the abstract to be considered late breaking, this section must be completed). • Ensure that submission of the abstract follows the general abstract submission guidelines and regulations and the specific guidelines listed above • Ensure abstracts that include clinical trial data include the following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), analysis, Trial status, Trial sponsor(s) • Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.
Selection • Abstracts will be judged solely on the data submitted. The first (presenting) author will receive confirmation of acceptance or rejection before 27 August 2011.
36
Back To table of contents
6. Embargo Policy for Late Breaking, Oral Presentations and Abstracts Selected for Media • Abstracts submitted to the 2011 European Multidisciplinary Cancer Congress are considered to be embargoed until the first day of the scientific programme • Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been published or presented at the 2011 European Multidisciplinary Cancer Congress • The first author and co-authors must not release the research/study to news media. • If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Abstract Topic Categories Sub-Topic
Topic
Sub-Topic
■■ Basic Science
■■ Drug Development
Aging and Cancer, Telomerase Animal Models of Cancer Cancer Cell Metabolism Cancer Initiating Cells/Cancer Stem Cells Cell Cycle, Cell Death, Senescence, Cell Profileration DNA Damage and Repair Epigenetics Functional Genomics Gene Expression, Transcriptional Regulation Genomic Alterations in Cancer miRNA Oncogenes Receptors and Signal Transduction Tumour Suppressor Genes Tumour Angiogenesis Tumour Microenvironment Tumour Progression: Invasion and Metastasis Tumour Immunology Viral Oncogenesis
Angiogenic Inhibitors Apoptosis Inducers Cyclins and CDKs DNA Repair Mechanisms Drug Design Drug Resistance and Modifiers Drug Screening Drug Synthesis Formulation Research Immunological Targets Monoclonal Antibodies and Targeted Toxins/Nuclides Natural Products and Marine Compounds New Molecular Targets Radiation Interactive Agents Signal Transduction Modulators Telomerase- Targeting Agents Topoisomerase Inhibitors Toxicology Tubulin-Interacting Agents Tumour Stem Cells Tyrosine Kinase Inhibitors Vaccines Other
■■ Breast Cancer - Advanced Disease Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Breast Cancer – Early Disease Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Cancer in the Older Patient Epidemiology Multi-Modality Radiotherapy Surgery Symptom Science Systemic Therapy Other
■■ Central Nervous System Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Diagnostic/Biomarkers Expression Profiling Predictive Biomarkers Prognostic Biomarkers Other
CALL FOR ABSTRACTS
Topic
■■ Epidemiology and Prevention General Epidemiology Molecular Epidemiology Primary Prevention Secondary Prevention Other
■■ Gastrointestinal Malignancies -
Colorectal Cancer Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Gastrointestinal Malignancies -
Noncolorectal Cancer Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Genitourinary Malignancies -Other Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Genitourinary Malignancies -Prostate Cancer Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
37
Topic Sub-Topic
Sub-Topic
■■ Gynaecological Cancer
■■ Oncology Nursing
Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
Advanced Nursing Roles Impact of Cancer on Patients and Families New Developments Supportive and Palliative Care End of Life Care Survivorship and Rehabilitation Symptom Management Transitions in Care Other
■■ Haematological Malignancies and Myeloma Basic Science Radiotherapy Systemic Therapy Translational Research Other
■■ Head and Neck Cancer
Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Imaging CT-Scan Molecular Imaging MRI New Methdologies Nuclear Medicine US Other
■■ Lung cancer - Localised / Local Regional Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Lung Cancer - Metastatic Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
■■ Melanoma and Skin Cancer Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
38
Topic
■■ Paediatric Oncology
■■ Public Health, Health Economics, Policy
■■ Radiobiology/Radiation Physics/
Radiotherapy Techniques Advanced Technologies Biomarkers for Radiation Oncology Clinical radiation Physics Clinical Radiobiology Combined Treatments Frontiers in Radiation Oncology Health Economics in Radiation Oncology Imaging for Radiotherapy Mathematics and IT for Radiation Oncology Modification of radiation response Monitoring in Radiotherapy Multiprofessional Team Development Prediction and Stratification in Radiation Oncology Professional Development Quality Assurance Radiation Physics Radiobiology Radiotherapy Outcome Assessment Radiotherapy Techniques Radiotherapy Technologies Technology Assessment in Radiation Oncology Treatment Planning Other
■■ Regulatory/Trial Methodology/Pharmacy
■■ Surgical Techniques Image-Guided Surgery Local Ablative Treatment Oncoplastic Surgery Regional Treatment Robotic-Assisted Surgery Other
■■ Sarcoma: Soft Tissue and Bone Basic Science Multi-Modality Radiotherapy Surgery Systemic Therapy Translational Research Other
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Sub-Topic
Topic
Sub-Topic
■■ Symptom Science
■■ Onco-Technology
Palliative Care Psychosocial Aspects Quality of Life Supportive Care Other
Basic Medical Engineering Clinical Medical Engineering Computational Models of Biological Systems DNA Detection Technologies Integrated Biology Internet Technology for Oncology Nanotechnology New Imaging Technologies New Non-Ionizing Radiation Treatment Technology New Treatment Technologies: Ionising Radation Novel Communication Systems Novel IT for Oncology Novel Navigation Systems Oncology Information Systems Patient Safety Systems Technology Proteomics/Mass Spectrometry RNA Detection Technologies Telemetry and Cyber Physical Systems for Oncology Tele-Oncology Other
■■ Translational Research Antibody Based Therapies Biomarkers with Clinical Relevance Cancer Genomics & Bioinformatics Cancer Vaccine Therapies Cellular Therapies Emerging Targets Epigenetics Inflammation and Cancer Molecular Biology in the Clinic Molecular Pathology Prognostic Biomarkers of Therapy Response Prognostic Value of Oncogenomics Signalling Pathways Tumour Microenviroment Other
CALL FOR ABSTRACTS
Topic
■■ Other
The open access cancer journal from the
Organisation of European Cancer Institutes
Leading cancer communication in Europe journal - Open access journal from the European Institute of Oncology - No subscription charges - Independent, not for profit - Fast turnaround of articles
Founding partners
Founding charities
- Over 700 interviews with leading experts - Watch, comment and share Over 30,000 users from 191 countries Over 100 articles and more than 700 videos
BE PART OF THE COMMUNITY AT www.ecancer.eu
Essential information. Trusted Source. On-demand
Back To table of contents
39
Fellowship Grants & Educational Awards 1. The 2011 European Multidisciplinary Cancer Congress Fellowship Grants Through the generosity of the 2011 European Multidisciplinary Cancer Congress Sponsors, a number of Fellowship Grants are offered to young researchers (doctors, basic scientists and nurses) from countries with limited resources to attend the Congress. To meet the requirements to be considered for a fellowship grant the applicant should: • Submit an abstract for the 2011 European
2. ECCO/EJC Young Investigator’s Award ECCO – the European CanCer Organisation and EJC European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator’s Award, to be presented at 2011 European Multidisciplinary Cancer Congress. The ECCO/EJC Young Investigator’s Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.
Multidisciplinary Cancer Congress. Applicants whose abstracts have been accepted for an oral or poster presentation at the 2011 European Multidisciplinary Cancer Congress will be considered first. • Be under the age of 40 and have a primary focus in clinical or experimental oncology or cancer nursing. • Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support, including a copy of the submitted abstract. • Provide a two page CV (including date of birth). The deadline for receipt of applications is 18 April 2011 (abstract submission deadline). Incomplete applications will not be considered.
Each Fellowship Grant shall be worth a free registration, free accommodation for a maximum of 4 nights and reimbursement of travel costs up to a maximum of 500 EUR (reimbursement after the Congress). Please complete the online application form on the ECCO website at: www.ecco-org.eu.
40
Back To table of contents
The following application criteria will apply: • Candidates should be junior (within 5 years of completion of PhD or specialist training). • Candidates should have completed the submitted work in the period between April 2009 and April 2011. • Submissions should be sent in by the candidate together with a reference letter from their Head of Department. • The work may be the result of individual research or the result of a thesis completed in the field of basic, translational or clinical research. • Candidates should commit themselves to write an original paper in English on the scientific work carried out (for publication in EJC).
The application should include the following documents: • A summary of the research work (maximum 2 pages) and copies of recently published or submitted manuscripts of the applicants work, to be submitted in English. • A curriculum vitae and a list of publications. • A supporting letter from the Head of Department.
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Deadline for applications: May 15, 2011.
Applications should be sent to Simona Androni, Scientific Programme Co-ordinator via Email: simona.androni@ecco-org.eu. Successful applicants will be notified in the course of July 2011.
3. ECCO – the European CanCer Organisation/ EJC Young Investigator’s Poster Awards
FeLLOWSHIP GRANTS & EDUCATIONAL AWARDS
Applications will be reviewed by the 2011 European Multidisciplinary Cancer Congress Committee Chairs and the Editor-in-Chief of EJC. The winner of the ECCO/EJC Young Investigator’s Award will receive a prize of 4000 EUR, free registration for the 2011 European Multidisciplinary Cancer Congress, free accommodation in Stockholm for the period of the Congress and reimbursement of travel expenses and the opportunity to give an oral presentation of the work at 2011 European Multidisciplinary Cancer Congress.
We are also pleased to announce the ECCO/EJC Young Investigator’s Poster Awards, which will be selected and presented during the 2011 European Multidisciplinary Cancer Congress. This Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for original work in cancer research, treatment or care.
The following further application criteria will apply: • Candidates should be junior (within 5 years of completion of PhD or specialist training). • Candidates should have submitted an abstract to the congress. • Candidates must indicate that they are young investigators when submitting their abstract.
Selection of the award winners will be made by the Scientific Chairs during the Congress and there will be three awards which will be presented throughout the meeting.
Back To table of contents
41
Registration Registration is now open online - please visit: www.ecco-org.eu.
(select ‘Congresses and conferences’ ). Participants are encouraged to register early in order to benefit from significant savings on fees: ‘Deadline’ applies to both receipt of registration and payment
Early Rate Deadline: 04 April 2011
Regular Rate Deadline: 08 August 2011
Late Rate As of 09 August 2011
Members *
475 EUR
695 EUR
1,095 EUR
Non-Members
695 EUR
995 EUR
1,095 EUR
Emerging Economy Rate **
125 EUR
Not available
Not available
Nursing Rate ***
375 EUR
475 EUR
575 EUR
170 EUR
170 EUR
170 EUR
225 EUR
225 EUR
225 EUR
Students/Junior Participant ‘in training’ **** Patient Advocate***** Spouse Ticket ******
95 EUR
All registration fees include local VAT (25%).
* Discounted membership rates apply for individuals who are member of one of the following professional associations: EACR, ESMO, ESSO, ESTRO, SIOPE, EANO, EAU, EORTC, ESGO, ESO, ESOP, EUSOMA, BIG, EANM, EBMT, ECL, FAC, OECI, UICC. ** Emerging Economy Rate is applied to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: http://data.worldbank.org/about/country-classifications/ country-and-lending-groups *** Including EONS Members **** Confirmation of ‘in training’ status and a letter from the Head of Department is required. These documents have to be sent to the 2011 Stockholm Congress Secretariat by Fax: +32 2 775 02 00. ****** Including members of EUROPA DONNA, EUROPA UOMO, Euroskin, Myeloma Euronet. ****** This ticket includes access to the Welcome Reception on Friday, 23 September 2011 as well as a Sightseeing Tour of Stockholm on Saturday, 24 September 2011. Please note: access to Scientific Sessions or the Exhibition is NOT permitted.
For information regarding group registration, accommodation and travel through the 2011 Stockholm Congress officially appointed local housing agent and airline network please visit: www.ecco-org.eu (select ‘Congresses and conferences’).
42
Back To table of contents
The 2011 European Multidisciplinary Cancer Congress
Integrating basic & translational science, surgery, radiotherapy, medical oncology & care stockholm, 23-27 SEPTEMBER 2011
www.ecco-org.eu
Title & Contact Details Prof.
Dr.
Last Name:
Mr.
Mrs.
Ms.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Institute/Company:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Address: City:
First Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Department:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International Tel. Number: Email:
Registration Form
REGISTRATION
Registration Form
Postcode:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
..........................................
Country:
International Fax Number:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Billing Address Institute/Company:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Address:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
City:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Country:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International Tel. Number: Email:
Postcode:
.........................................................................................................................................
VAT Number:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International Fax Number:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Specialisation in Main Tumour Types (Please select all that apply) Breast Bladder Blood Bone Brain Colorectal Cervix Head and Neck
Kidney Liver Lung Melanoma and Skin Neuroendocrine Ocular Ovarian Pancreatic
Prostate Soft Tissue Sarcoma Stomach Thyroid Other All
Area of Main Interest (Please select all that apply) Advocacy Basic Science Clinical Research Drug Development Early Drug Development Geriatric Oncology
Nursing Paediatrics Palliative Care Pathology Pharmacy Psychosocial Oncology
Policy Radiotherapy Systemic Therapy Surgery Translational Research Other
Neurologist Neuro-oncologist Neuro-surgeon Nurse Oncology pharmacist Paediatric oncologist Patient advocate Pathologist
Radiologist Radiotherapist Statistician Student Surgical oncologist Translational scientist Urologist Other
EORTC ESGO ESMO ESO ESOP ESSO ESTRO Europa Donna
Europa Uomo EUROSKIN EUSOMA Flims Alumni Club Myeloma Euronet OECI SIOP (Europe) UICC
Profession Basic scientist Clinical trial coordinator General physician General surgeon Gynaecologist Haematologist Medical affairs Medical oncologist
Professional membership BIG EACR EANM EANO EAU EBMT ECL EONS
Back To table of contents
43
Registration fees (please tick as appropriate) ‘Deadline’ applies to both receipt of registration and payment
Early Rate Deadline: 04 April 2011
Regular Rate Deadline: 08 August 2011
Late Rate As of 09 August 2011
Members *
475 EUR
695 EUR
1,095 EUR
Non-Members
695 EUR
995 EUR
1,095 EUR
Emerging Economy Rate **
125 EUR
Nursing Rate ***
375 EUR
Not available 475 EUR
Not available 575 EUR
Students/Junior Participant ‘in training’ ****
170 EUR
170 EUR
170 EUR
Patient Advocate *****
225 EUR
225 EUR
225 EUR
95 EUR
Spouse Ticket ******
All registration fees include local VAT (25%). *
Discounted membership rates apply for individuals who are member of one of the following professional associations: EACR, ESMO, ESSO, ESTRO, SIOPE, EANO, EAU, EORTC, ESGO, ESO, ESOP, EUSOMA, BIG, EANM, EBMT, ECL, FAC, OECI, UICC.
**
Stating the membership number is obligatory:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Emerging Economy Rate is applied to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: http://data. worldbank.org/about/country-classifications/country-and-lending-groups
***
Including EONS Members
****
Confirmation of ‘in training’ status and a letter from the Head of Department is required. These documents have to be sent to the 2011 Stockholm Congress Secretariat by Fax: +32 2 775 02 00.
***** Including members of Europa Donna, Europa Uomo, Euroskin, Myeloma Euronet. ****** This ticket includes access to the Welcome Reception on Friday, 23 September 2011 as well as a Sightseeing Tour of Stockholm on Saturday, 24 September 2011. Please note: access to Scientific Sessions or the Exhibition is NOT permitted.
Method of payment / credit card type Paid by credit card (preferred) Eurocard/Mastercard Card Number:
Visa
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Owner’s name as shown on the card:
American Express Expiry Date: .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Control/CVC-Code:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Please charge the above mentioned credit card for my registration to the European Multidisciplinary Cancer Congress.
Date:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Owner’s signature:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Remitted by bank transfer (accepted until 29 August 2011 in EUR) To the 2011 Stockholm Congress Registration Account Account number: 733-034 89 79-03 // IBAN BE21 7330 3489 7903 BIC/SWIFT Code: KREDBEBB // KBC Bank, Chaussée de Wavre 1662, B-1160 Brussels, Belgium Please clearly indicate the name of the participant and 2011 Stockholm Congress in all your remittances. REPLACEMENTS AND CANCELLATIONS
Replacements (= delegate name change) of confirmed registrations are subject to a charge of 95 EUR per participant. Cancellations of confirmed registrations are subject to a charge of 125 EUR per participant provided the cancellation is received by 08 August 2011. For cancellations received after this date no refunds will be made. By completing this form I accept the terms and conditions of registration mentioned above. If posting or faxing please sign and date below. Date: Signature: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44
Back To table of contents
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The 2011 European Multidisciplinary Cancer Congress Secretariat can be reached at: ECCO – the European CanCer Organisation Avenue E. Mounier 83 - B 1200 Brussels - Belgium Telephone: +32 2 775 02 00 - Fax: +32 2 775 02 01 - Email: registration@ecco-org.eu
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
Scientific Programme Tracks: Chairs & Experts ■■ Drug Development
■■ Genitourinary Malignancies - Other
Track Chair
C. Dive
UK
Track Chair
J. Baselga
ES
Track Chair
J. Bellmunt
ES
Track Chair
R.J. White
UK
Track Chair
S. Sleijfer
NL
Track Chair
P. Hoskin
UK
J. Celis
DK
E. Calvo
ES
M. De Santis
AT
N. Cordes
DE
F.Cardoso
BE
A. Kiltie
UK
G. Giaccone
USA
FR
Z. Kirkali
TR
J. Seoane
ES
E. Cohen-JonathanMoyal
S. Oudard
FR
K. Wiman
SE
S. Marsoni
IT
B. Wouters
CA
H. Newell
UK
P. Workman
UK
■■ Breast Cancer - Advanced Disease Track Chair Track Chair
J. Bergh
SE
■■ Education Track
■■ Genitourinary Malignancies -
Prostate Cancer Track Chair
K. Fizazi
FR
Track Chair
M-O.Grimm
DE
D. Schrijvers
BE
C. Belka
DE
R. Stahel
CH
A. Bossi
FR
UK
J. De Bono
UK NL
F. Andre
FR
Track Chair
A. Di Leo
IT
Track Chair
T. Helleday
UK
R.A. Audisio
T. Kühn
DE
A. Barrett
UK
T. de Reijke
R. Orrechia
IT
A. Cervantes
ES
F. Guedea
ES
C. Swanton
UK
F. Ciardiello
IT
M.P. Matikainen
FI
C.J.H. van de Velde
NL
M. Dicato
LU
V. Jendrossek
UK
S.J. O'Connor
NL
Track Chair
S. Kaye
UK
N. Pavlidis
GR
Track Chair
P. Morice
FR
■■ Breast Cancer - Early Disease
■■ Gynaecological Cancer
Track Chair
C. Sotiriou
BE
R. Riccardi
IT
R. Brown
UK
Track Chair
J.R. Yarnold
UK
R. Soffietti
IT
N. Colombo
IT
S. Delaloge
FR
M. D'Incalci
IT
C. Isacke
UK
C. Haie-Méder
FR
M. Leidenius
FI
R. Pötter
AT
P. Poortmans
NL UK
C. P. Wild
FR
NO
R. Sainsbury
Track Chair
C.G. Tropé
IT
P. Hall
SE
CH
F. Sardanelli
Track Chair
A.T. Vlastos
S. Strömblad
SE
A. Gescher
UK
G. Vlastos
CH
B. Kocic
SR
N. Malats
ES
H. Storm
DK
Track Chair
V. Ribrag
FR
A.M. Thulstrup
DK
Track Chair
L. Bullinger
DE
J. Delabie
NO
■■ Gastrointestinal Malignancies -
M.H. Dreyling
DE
Colorectal Cancer
H.T. Eich
DE
T. Girinsky
FR
R. Küppers
DE
■■ Epidemiology, Primary and
Secondary Prevention
■■ Cancer in the Older Patient Track Chair
J.P. Droz
FR
Track Chair
J. Kazmierska
PL
R.A. Audisio
UK
C. Bokemeyer
DE
G-J. Liefers
NL
H. Langendijk
NL
S. Monfardini
IT
P. Scalliet
BE
Track Chair Track Chair
M. Hegi
■■ Haematological Malignancies
and Myeloma
Track Chair
E. Van Cutsem
BE
Track Chair
V. Valentini
IT
B.M. Ghadimi
DE
B. Glimelius
SE
K. Haustermans
BE
L. Påhlman
SE
Track Chair
S. Subramanian
RU
J. Tabernero
ES
Track Chair
K. Harrington
UK
I. Tomlinson
UK
A. Dietz
DE FR
■■ Central Nervous System CH
■■ Head and Neck Cancer
R. Grant
UK
S. Faivre
O. Chinot
FR
■■ Gastrointestinal Malignancies -
J. Giralt
ES
P. Lichter
DE
Noncolorectal Cancer
V. Gregoire
BE
R-O. Mirimanoff
CH
R. Knecht
DE
M. Merlano
IT
M. Preusser
AT
S. Short
UK
W. Wick
DE
■■ Diagnostic/Biomarkers
Scientific programme tracks
■■ Basic Science
Track Chair
R. Adam
FR
Track Chair
J. Llovet
ES
B. Bonsing
NL
T. Brunner
UK
D. Cunningham
UK
Track Chair
N. Lassau
FR
M.A. Gambacorta
IT
Track Chair
W. Weber
DE
■■ Imaging
Track Chair
F. Blackhall
UK
T. Lehnert
DE
S. Del Vecchio
IT
Track Chair
M. van de Vijver
NL
F. Lordick
DE
E. Even-Sapir
IL
P. Hainaut
FR
P. Friedl
NL
V. Lazar
FR
H-U. Kauczor
DE
B. Naume
NO
V. Khoo
UK
F. Penault-Llorca
FR
U. Nestle
DE
R.A.E.M. Tollenaar
NL Back To table of contents
45
■■ Industry
■■ Onco-Technology
■■ Sarcoma: Soft Tissue and Bone
Track Chair
D.R. Parkinson
USA
Track Chair
D.R. Olsen
NO
Track Chair
P. Hogendoorn
NL
Track Chair
M.L. Rothenberg
USA
Track Chair
C. Moonen
FR
Track Chair
P. Schöffski
BE
D. Chang
USA
R. Aebersold
USA
V. Budach
DE
S. Frings
USA
G. Beer
USA
I. Judson
UK
S. Johansson
SE
H. Boekne
USA
G. Kantor
FR
A. Riva
USA
F. Chen
BE
A. Le Cesne
FR
G. Saeter
USA
W. Enghardt
DE
P. Reichardt
DE
T. Suto
USA
R. Neumann
DE
J.M. Thomas
UK
M. Victor
FR
J.L. Pedraz
ES
H. von Busch
DE
C. von Kalle
DE
■■ Lung Cancer – Localised/
■■ Surgical Oncology Track Chair
Local Regional ■■ Paediatric Oncology
SE
R.A. Audisio
UK
S. Evrard
FR
Track Chair
T. Le Chevalier
FR
Track Chair
D. de Ruysscher
NL
Track Chair
R. Ladenstein
AT
T. Kovacs
HU
M. Brada
UK
Track Chair
G. Vassal
FR
T. Lehnert
DE
K.O. Byrne
IE
C. Carrie
FR
M. Leidenius
FI
FR
M. Gaze
UK
G. Poston
UK
S. Senan
NL
L.J. Hjorth
SE
C.J.H. van de Velde
NL
R. Stahel
CH
R. Riccardi
IT
P. Van Schil
BE
U. Ricardi
IT
M. Schrappe
DE
P. Dartevelle
■■ Lung Cancer - Metastatic ■■ Patient Advocacy/Ethics
■■ Symptom Science Track Chair
M. Aapro
CH
Track Chair
M. Di Palma
FR
S. Börjeson
SE
Track Chair
R. Dziadziuszko
PL
Track Chair
L. Paz-Ares
ES
Track Chair
L. Jost
CH
N.I. Cherny
IL
O.T. Brustugun
NO
Track Chair
S. Kyriakides
CY
C. Grau
DK
C. Le Pechoux
FR
A. Adamou
CY
E. Patiraki
GR
R. Perona
ES
I. Banks
UK
E. Ream
UK
J. Schirren
DE
R. Catane
IL
M. Wells
UK
M. Thomas
DE
N.I. Cherny
IL
J. Geissler
DE
T. Hudson
IT
A. Kienesberger
AT
■■ Melanoma and Skin Cancer Track Chair
A.M.M. Eggermont
NL
K. Oliver
UK
Track Chair
R. Marais
UK
NL
S. Aamdal
NO
E. Verschuur-van der Voort
M. Hocevar
SI
A. Waldmann
DE
C. Robert
FR
S. Schneebaum
IL
M.S. Soengas
ES
■■ Translational Research Track Chair
F. Cappuzzo
IT
Track Chair
M. Barbacid
ES
I. Ernberg
SE
P. Jänne
USA
M. Krause
DE
■■ Radiobiology/Radiation Physics/
Radiotherapy
■■ Oncology Nursing
J. Mazieres
FR
A.H. Ree
NO
M. Verheij
NL
Track Chair
J. Bourhis
FR
Track Chair
D. Zips
DE DK
Track Chair
E. Martinelli
IT
NL
Track Chair
D. Gabrys
PL CA
■■ Young Oncologists
Track Chair
S. Kav
TR
J. Alsner
Track Chair
L. Sharp
SE
J. Bussink
S. Faithfull
UK
E. Deutsch
FR
P. Bedard
UK
L. P. Muren
DK
M. den Dulk
NL
UK
J. Overgaard
DK
M. Hutka
PL
SE
H.P. Rodemann
DE
I. Konings
NL
FR
C. Massard
FR
P. Mordant
FR
L. Moreno
UK
J. Reis-Filho
UK
S. Rivera
FR
S. Schüle
DE
T. Yap
UK
D. Kelly A. Molassiotis Y. Wengström
M-C. VozeninBrotons
■■ Oncopolicy Track Chair
D. Kerr
UK
Track Chair
M. Baumann
DE
P.G Casali
IT
J. Celis
DK
A.M.M. Eggermont
NL
D. Khayat
FR
M. Piccart
BE
M. Pierotti
IT
K. Redmond
IT
U. Ringborg
SE
O. Wiestler
DE
■■ Regulatory/Trial Methodology/
Pharmacy
46
P. Naredi
Back To table of contents
Track Chair
A. Astier
FR
Track Chair
C. Dittrich
AT
J. Carmichael
UK
P. Hartvig
DK
D. Lacombe
BE
P. Lambin
NL
D. Parkinson
USA
F. Pignatti
UK
L. Serfass
FR
R. Terkola
AT
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
General Information
The 2011 European Multidisciplinary Cancer Congress Satellite Symposia will take place as follows: Friday 23 September 2011 11:00 – 13:00
Bayer Schering Pharma Dendreon
Congress Update Service
GENERAL INFORMATION
Commercially Sponsored Satellite Symposia
The Congress Update Service is the official Congress e-newsletter which has been specifically designed to help keep you fully informed about the latest Scientific Programme highlights, news and exciting developments. Each monthly newsletter will be archived on the Congress website to consult at leisure.
Lilly Oncology MSD Oncology Sandoz International Sanofi-aventis 13:00 – 16:00
Janssen
14:00 – 16:00
Celgene Cephalon Daiichi Sankyo Pfizer Oncology
14:00 – 17:00
Novartis Oncology
17:00 – 19:00
AstraZeneca Baxter Boehringer Ingelheim Novartis Oncology Pfizer Oncology Roche
Saturday 24 September 2011 18:30 – 20:00
Amgen Archimedes Pharma Bristol-Myers Squibb Merck Serono Novartis Oncology Pfizer Oncology Pfizer Oncology
Sunday 25 September 2011 18:45 – 20:15
Amgen
If you do not automatically receive each issue in your inbox and would like us to email you all future editions please contact us directly via Email at: ECCOcommunications@ecco-org.eu.
Exhibition The 2011 European Multidisciplinary Cancer Congress Exhibition represents an essential and integral element of the Congress, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the oncology field. The Organising Committee would gratefully like to thank and acknowledge the 2011 European Multidisciplinary Cancer Congress partners for their support and shared insight. To view the list of exhibitors, the latest information surrounding the Exhibition and detailed floor plans please visit: www.ecco-org.eu (‘Congresses and conferences’, ‘2011 Stockholm Cancer Congress’, followed by ‘Exhibition/Sponsorship’).
Astellas Pharma AstraZeneca GSK Oncology
Entrance is free for all registered participants. The exhibition will be open as follows:
Merck Serono 18:45 – 22:15
Bristol Myers Squibb
Monday 26 September 2011 18:30 – 20:00
Amgen
Saturday 24 September 2011 Sunday 25 September 2011 Monday 26 September 2011
09:30 – 16:30 09:30 – 16:30 09:30 – 16:30
Merck Serono Prime Oncology Sanofi-aventis
Companies, publishers and organisations that would like to participate in the exhibition can download the ‘Invitation to Industry’ from the Congress website: www.ecco-org.eu, or contact Bruno De Man via email: bruno.deman@ecco-org.eu or phone: +32 (2) 775 02 04. Back To table of contents
47
The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.
A valid passport is required for entry into Sweden. A visa may be required for some countries. For information about visa and passports contact your local Swedish Embassy at least 3 months prior to your departure to join us in Stockholm.
Language and Translation
Transportation
Insurance
The official language of the Congress is English. No simultaneous translation will be provided.
Lunch and Refreshments Lunch or refreshments are not included as part of the registration fee.
Official Carrier
Save up to 20% on travel with the Star Alliance network.
The Star Alliance™ member airlines are pleased to be appointed as the Official Airline Network for the 2011 European Multidisciplinary Cancer Congress To obtain the Star Alliance Conventions Plus discounts, please quote the event code SK 03A23 when calling the reservation office of a participating Star Alliance member airline. For booking office information please visit: www.staralliance.com/conventionsplus
Registered participants plus one accompanying person travelling to the event can be granted a discount of up to 20%, depending on the fare and class of travel. The participating airlines for this event will be announced: www.ecco-org.eu. Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares. Please note: For travel from Japan and New
Zealand, special fares or discounts are offered by the participating airlines on their own network.
48
Back To table of contents
Participants registered for the entire duration of the European Multidisciplinary Cancer Congress are entitled to one free public transport ticket.
Opening Event The 2011 Stockholm Cancer Congress Opening Event will take place on Friday 23 September from 19:30 onwards in Hall A1 of the Congress Centre. In celebration of the largest and premier cancer meeting in Europe, we invite you to what promises to be an unforgettable evening in the company of friends and guests as well as enjoy a trio of live entertainment followed by a welcome reception serving local fare, delicacies and drinks.
THE 2011 EUROPEAN MULTIDISCIPLINARY CANCER CONGRESS
1.
As of 2011 we are bringing together the 16th ECCO, 36th ESMO , 30th ESTRO Congresses to form the European Multidisciplinary Cancer Congresses. Organised in partnership with ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE, these Congresses are the premier European cancer meetings.
2.
They represent the largest European platform at which to present the latest, ground-breaking data with a late breaking submission policy to capture even more abstracts with practice changing data.
3.
Global visibility. Building on the media interest and widespread international coverage of our previous Congresses, the 2011 European Multidisciplinary Cancer Congress promises an even stronger media campaign to increase exposure.
4.
The European Multidisciplinary Cancer Congresses are European meetings without boundaries. Our 2011 Stockholm Congress will build on the successes of the 2009 Congress which attracted a record, global participation of almost 15.000 from a total of 110 countries.
5.
The 33 Scientific Tracks will guarantee the multidisciplinary and multi-professional appeal unique to our Congresses. For the first time ever, we will incorporate 5 brand new Tracks including Industry as well as Oncotechnology.
6.
The Comprehensive Scientific Programme of excellence is currently being devised by a record number of over 150 scientific experts, ensuring exceptional quality and educational opportunity.
7.
The European Multidisciplinary Cancer Congresses are the largest ACOE/EACCME Accredited events in Europe. ACOE accreditation not only provides delegates with a guarantee of high quality and unbiased educational activity but CME credits gained are recognised by most of the national CME authorities in Europe.
8.
Our Congresses are the only European cancer meetings to promote and foster continued improvement at EU Level through a dedicated Oncopolicy Track. Embracing all stakeholders in oncology, the Track is specifically tailored to address and tackle issues of prime importance to the European cancer community head-on.
9.
The 2011 Stockholm Congress will of course incorporate the usual favourites including the not-to-be-missed legendary oxford style debates, educational symposia, the highly topical teaching lectures and much more.
Top 10 reasons te attend
The 2011 Stockholm Cancer Congress: Top 10 Reasons to Attend
10. Stockholm, capital of Sweden, is synonymous with beauty – ask any of its visitors! Host city to the 2011 European Multidisciplinary Cancer Congress, 23 – 27 September 2011, Stockholm is also treasured for its cultural diversity, architecture, abundant clean and open water, and its many parks. Built on 14 islands and connected by a total of 57 bridges, this captivating city will enchant and entertain us all.
Back To table of contents
49
Accommodation & Local Services
Accommodation
Local Services
MCI - Stockholm Office has been appointed as the official local housing partner for the 2011 European Multidisciplinary Cancer Congress and is offering hotel accommodation, tours and excursions for both groups and individuals.
Ovation Scandinavia has been appointed to offer a wide range of services during the 2011 European Multidisciplinary Cancer Congress to help you, the participants, make the most of your stay with us in Stockholm!
For information and queries please contact:
With extensive experience in event management coupled with a broad network of contacts, companies and service providers locally, you can rely on Ovation Scandinavia to find you the very best.
MCI – Stockholm Office Box 6911 SE-102 39 Stockholm Email: stockholm11@mci-group.com Tel: +46 8 5465 1500 Fax: +46 8 5465 1599 We kindly ask you to contact the appointed local housing partner DIRECTLY. Please do NOT contact the Congress Secretariat for this information.
Just some of the many services that Ovation Scandinavia can organise and manage for you include: • Transportation • Meetings (outside the Congress Centre) • Receptions (outside the Congress Centre) • Dinners
Delegates are encouraged to book online via www.ecco-org.eu. All rooms are booked on a first come first served basis. The deadline for hotel reservation is 1 August 2011. After this date accommodation cannot be guaranteed by MCI – Stockholm Office.
• Other social events outside the hours of the official Congress Scientific Programme • On site staff • Tours • Room gifts • Phone rental
For further information, please contact: Ovation Scandinavia Tel: +46 (0)8 458 72 70 Email: Scandinavia@ovationdmc.com
50
Back To table of contents
The 2011 European Multidisciplinary Cancer Congress
Integrating basic & translational science, surgery, radiotherapy, medical oncology & care stockholm, 23-27 SEPTEMBER 2011
www.ecco-org.eu
Accommodation Form MCI – Stockholm Office P.O. Box 6911 S - 10239, Stockholm, Sweden
Accommodation Form
PLEASE COMPLETE AND RETURN TO:
Email: stockholm11@mci-group.com Telephone: +46 8 5465 1500 Fax: +46 8 5465 1599
HOTEL ACCOMMODATION - DEADLINE: 01 AUGUST 2011
Please note that the organiser would prefer online bookings at: www.ecco-org.eu PLEASE COMPLETE BY USING TYPEWRITER OR CAPITAL LETTERS
General Data - Participant Prof.
Dr.
Check-in date: Last Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
City:
Mrs. Check-out date:
home address
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First Name:
No. of nights:
work address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinic / Department:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
International Tel. Number: Email:
Ms.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Institute/Company: Address:
Mr.
Postcode:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
..........................................
Country:
International Fax Number: Mobile:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
General Data – Accompanying Person(s) Last Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Last Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
First Name:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hotel Accommodation Single room SEK/night
Double room SEK/night
Walking distance to commuter train
Adlon Hotel
1895 SEK
2195 SEK
4 minutes
Anno 1647
1940 SEK
2390 SEK
15 minutes
BW Hotel Terminus
2005 SEK
n/a
2 minutes
1565 SEK
2000 SEK
15 minutes
Central Hotel
2280 SEK
2280 SEK
5 minutes
Comfort Hotel Stockholm
1795 SEK
n/a
3 minutes
Hotel
BW Kom Hotel
Category
(no classification)
First Hotel Amaranten
(no classification)
2650 SEK
3350 SEK
10 minutes
First Hotel Reisen
(no classification)
2850 SEK
3150 SEK
15 minutes
Hotel Esplanade
1895 SEK
n/a
20 minutes
Hotel Hellsten
2390 SEK
2490 SEK
20 minutes
Hotel Riddargatan
2020 SEK
2390 SEK
20 minutes
Hotel Skeppsholmen
(no classification)
2415 SEK
3185 SEK
20 minutes
Lady Hamilton Hotel
(no classification)
3190 SEK
3690 SEK
15 minutes
Lord Nelson Hotel
(no classification)
2090 SEK
2390 SEK
15 minutes
Nordic Sea Hotel
(no classification)
2050 SEK
n/a
3 minutes Back To table of contents
51
Single room SEK/night
Double room SEK/night
Walking distance to commuter train
Radisson Blu Royal Viking
3095 SEK
3295 SEK
1 minute
Rex Hotel
1990 SEK
2290 SEK
15 minutes
Rica Hotel Gamla Stan
1995 SEK
2195 SEK
15 minutes
Rica Hotel Kungsgatan
1895 SEK
n/a
5 minutes
Rica Hotel Stockholm
1895 SEK
n/a
5 minutes
Hotel
Category
Scandic Malmen
(no classification)
2190 SEK
2590 SEK
6 minutes
Scandic Norra Bantorget
(no classification)
1890 SEK
1990 SEK
5 minutes
1735 SEK
2035 SEK
6 minutes
Zinkendamms Hotel
Special requests (i.e. type of room, sharing double room with): . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rates are given in SEK, include breakfast buffet, service and 12% VAT. Further information and a city map can be found at: www.ecco-org.eu. Please note: as the Congress takes place during a busy period in Stockhom we recommend you arrange your
accommodation at your earliest convenience.
Guarantee/Payment No reservation will be confirmed unless MCI has received your credit card details as a guarantee of your hotel reservation. All hotel costs are to be settled directly with the hotel. Please note: the deadline for hotel reservation is August 1, 2011. After this date available rooms or the
preferential rate cannot be guaranteed. In the event of the preferred hotel or room type being fully booked, MCI reserves the right to book another alternative available. Once MCI has confirmed your room, the reservation is considered guaranteed.
Cancellation Until July 17, 2011: Cancellation fee of SEK 500 per cancelled room. As from July 18, 2011 and until August 5, 2011: Cancellation fee representing 50% of the value for the cancelled nights. As from August 6, 2011: Cancellation will be charged with a cancellation fee representing 100% of the value for the cancelled nights. The cancellation fee, if any, will be charged to your credit card mentioned below.
Credit Card Guarantee and Payment of Cancellation Fee: Eurocard/Mastercard
Diners Club
Card no: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Expiry Date: .
Visa
American Express
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Owner’s name as shown on the card: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Control/CVV-Code: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Date: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Card Owner’s signature: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52
Back To table of contents
SAVE UP TO 20% ON GETTING TO YOUR CONVENTION WITH CONVENTIONS PLUS It’s easy to save money on your flights if you fly the Star Alliance™ network. Simply quote the event code SK03A23 when you make your booking with any Star Alliance member airline and you’ll automatically get a discount of up to 20%. The Star Alliance network has 27 member airlines with over 21,000 flights a day so we can offer you a lot more choice when planning your travel. For more information about our member airlines and contact details, please visit our website at www.staralliance.com/conventionsplus
www.staralliance.com Information correct as at 09/2010
, LET S THINK BoEHRINgER INgELHEIm IS CommITTED To oNCoLogY AND ADvANCED RESEARCH IN THE AREAS of: Angiogenesis Inhibition Signal Transduction Inhibition Cell-Cycle Kinase Inhibition www.inoncology.com
Copyright Š2010. Boehringer Ingelheim Pharmaceuticals Inc All Rights Reserved 201006179